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Mycobacterium tuberculosis (Mtb) is the causative agent of Tuberculosis (TB), a life-threatening 
disease primarily affecting the lungs that infects about one third of the world‘s population and 
causes 1.3 million deaths annually. It is estimated that TB has been infecting humans for around 
70,000 years and has killed more people than any other infectious disease. The highly effective, 
persistent, and multifaceted virulence strategies that have allowed Mtb to continue to spread and 
thrive for so long are still poorly understood at the molecular level. This lack of knowledge 
contributes to ongoing challenges to curing TB. Although drugs capable of killing Mtb exist, even 
strains that are susceptible to these drugs remain so difficult to treat that stringent six- to nine-
month courses of four-drug cocktails are required. Practical difficulties in administering full 
treatments and patient noncompliance have contributed to a rise in drug-resistant TB cases globally. 
To combat this increasing world health problem, new antibiotic treatments that kill Mtb and drug-
resistant Mtb more effectively via new mechanisms of action are necessary. Discovering these 
antibiotics expediently requires that innovative Mtb-specific drug-screening assays are developed. 
 An ideal and innovative TB drug screening method would target validated protein-protein 
interactions (PPI) essential to Mtb‘s pathogenesis and would be performed on whole Mtb cells 
under relevant in vivo-like conditions. This project focused on engineering several tools relevant to 
creating an ideal TB drug screen. A protein fragment complementation assay capable of studying 
PPI of the TB gyrase complex was created, and this assay was assessed for future HTS applications. 
To streamline the readout, this assay was re-engineered to include green fluorescent protein. 
Modifications to the red fluorescent protein mCherry, including the creation of a large Stokes shift 
mutant mCherry and an mCherry bimolecular fluorescence complementation assay, were also 
engineered and investigated.  
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CHAPTER ONE: AN OVERVIEW OF TUBERCULOSIS 
1.1 Tuberculosis: A Persistent World Health Problem 
 Mycobacterium tuberculosis (Mtb) is the bacterium that causes the respiratory disease 
Tuberculosis (TB) which, according to the World Health Organization (WHO), was responsible for 
the deaths of 1.3 million people in 2013 [1]. In the same year, 8.6 million people were newly infected 
with Mtb, contributing to the estimated 33% of the world‘s population that is latently infected with 
TB [1, 2]. The most heavily affected regions are in Asia and Africa, especially in very densely 
populated countries like India [3]. TB continues to spread and thrive because it features highly 
effective, persistent, and multifaceted virulence strategies that are still poorly understood, as well as a 
pattern of infecting populations that are prominently afflicted with human immunodeficiency virus 
(HIV) like those in Sub-Saharan Africa [3].  
The toll on human life and health caused by Mtb is not a new problem. In fact, it is thought 
that more people have died from TB throughout history than from any other infectious disease [4]. 
Humans have been afflicted with TB for about 70,000 years, and it is this remarkable ―timelessness‖ 
in the face of human lifestyle changes and advances in modern medicine over millennia that makes 
the puzzle of curing TB both interesting to study and challenging to unravel [4]. Despite global 
tuberculosis reports by the WHO that imply TB is gradually declining, other evidence suggests that 
TB still ought to be treated as a growing world health problem [5]. For example, more people are 
currently afflicted with the contagious form of TB than at any other time in history, and global 
control of the disease is dually threatened by the emergence and spread of drug-resistant TB [4, 5]. 
Considering these challenges alongside the ongoing lag in production of improved antibiotics to 
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combat them, it is important that we advance our knowledge of the pathogenesis of Mtb. Hopefully 
we can exploit this knowledge to generate more effective treatments for TB in the future, mitigating 
TB‘s global detrimental impact. 
1.2 Basic Pathogenesis of Mtb 
Critical to the spread, survival, and evolution of Mtb is its ability to cause infection and 
disease in a human host. The primary site of infection is the alveolar space. Depending on the 
interactions between the host and the bacteria following the initial infection, two distinct disease 
states are observed: latent or active TB. In 90% of cases, infection with Mtb does not result in an 
active disease state, at least at first, because the immune system contains the pathogen inside walled 
off, aggregated clusters of immune cells called granulomas in the lungs [3]. This containment in 
many cases may sterilize the infection, particularly if the rate at which Mtb is attacked by the 
adaptive immune response is relatively high [6]. However, Mtb is often able to survive the host‘s 
defenses, remaining dormant in the body inside these granulomas. This is termed a latent 
tuberculosis infection. From inside this niche, Mtb is able to continue its life cycle, using specialized 
virulence factors to take advantage of the latent infection and persist until the host‘s immune 
defenses break down. At this point, Mtb escapes its replicative niche and becomes transmissible via 
aerosolized droplets, which is termed active TB.  
Unlike other highly successful bacterial diseases—cholera, typhoid, plague, and diphtheria, to 
name a few—the causative agent of TB does not feature many of the virulence factors that are 
classic to these other pathogens [4]. For example, it is notable that Mtb features no capsule for 
evading phagocytosis, no pili or adhesins for attaching to host tissue, no flagella for motility, and few 
enzymes or toxins with which to damage host cells [4]. Rather, Mtb‘s pathogenic lifecycle has been 
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honed so that it does not need these virulence factors to establish disease; Mtb sidesteps innate 
immune system barriers and hijacks host macrophages in order to reach deep sterile sites and cause 
infection [4]. Normally a pathogen is engulfed by macrophages via phagocytosis and a 
phagolysosome forms containing degradative enzymes and toxic molecules to destroy the pathogen, 
but Mtb is able to survive inside the host macrophages. Mtb does this by manipulating phagosome 
maturation to avoid acidification and fusion with the lysosome. From this point, Mtb is able to 
continue evading, modifying, and exploiting both the adaptive and innate immune system to further 
disease in its host.  
Infection with Mtb is initiated via an aerosolized form of the bacteria that is produced when 
individuals who are in the contagious, or ―active‖ stage, of TB cough in the vicinity of others. Upon 
inhalation, small droplets containing one to three bacteria enable Mtb to access lower lung tissue and 
to begin establishing disease by engaging with alveolar macrophages [4]. Mtb’s surface is awash in 
pathogen-activated molecular patterns (PAMPs) that would typically activate Toll-like receptor 
(TLR)-mediated signaling to recruit microbicidal macrophages, which are primed to destroy invading 
mucosal pathogens. However, pathogenic mycobacteria express a surface lipid that masks their 
PAMPs and reduces the activation of TLRs to save them from destruction by these innate immune 
cells [4]. Additionally, Mtb is able to express a related surface lipid that triggers recruitment of 
growth-permissive macrophages that allow Mtb to invade them [4]. This strategy is aided by the 
small infectious droplets delivering Mtb directly to the alveolar space in the lower lung, where few 
commensal bacteria exist to stimulate TLR-signaling and ruin Mtb‘s disguise [4]. The fact that 
alveolar macrophages are programmed not to induce strong inflammatory responses upon engulfing 
pathogens that enter the alveolar space is also conducive to the initial establishment of the infection 
[7].  
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The growth-permissive macrophages first recruited by Mtb to its entry site become infected 
with the bacteria, and the bacteria are subsequently transported across the epithelium of the lung to 
deeper tissues [4]. Migratory immune cells of the host respond to the early infection by transporting 
some of the bacteria to nearby lymph nodes [6]. Here, the process of generating T cells that are 
primed to act against Mtb begins; although, about two weeks elapse between Mtb entering the 
alveoli and the beginning of this adaptive immune response [6]. In this time, the early stage infection 
gives way to expansion as new groups of growth-permissive macrophages are recruited by Mtb and 
subsequently infected [4]. The initially infected macrophages die via apoptosis once the number of 
bacteria inside them is sufficiently high [4]. Still containing viable bacteria, the dead macrophage 
contents are engulfed by the newly recruited macrophages to expand the infection [4]. By the time 
antigen-specific CD4+ T cells proliferate in the lymph node and are distributed to the infection site, 
their ability to reach infected macrophages and aide in resolving the disease is limited by excessive 
accumulation of recruited macrophages around the infection site [6]. As the host‘s immune response 
advances, the bacteria eventually cause granuloma formation in the lungs through an intricate 
process of manipulation and subsequent aggregation of macrophages and other immune cells into 
these tightly-linked, epithelioid clusters [4]. In this way, the granuloma exists alongside the expansion 
of Mtb’s niche in the host, as Mtb continues to transcriptionally induce new genes it needs to adjust 
to the ever more hostile environment of the growing granuloma. An adaptive immune response to 
Mtb‘s expansion of the granuloma may wipe out the tubercle bacteria, but in many cases the 
mycobacteria employ further strategies to persist against the adaptive immune system. For example, 
it is believed that by delaying the priming, arrival, and activation of T cells while continuing to delay 
responsiveness of macrophages, Mtb is able to hold on to its replicative niche long-term [4]. From 
the host‘s perspective, combatting Mtb becomes a delicate balance. On one hand, the immune 
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response must contain the bacteria to prevent it from disseminating outside the granuloma and 
infecting other organs [6]. On the other hand, the immune response must be tempered to prevent 
excessive inflammation that hinders the efficacy of the adaptive response and causes collateral tissue 
damage [6].  
After forming a mature granuloma, the final step in Mtb‘s life cycle is to escape from the 
granuloma so it can exit its host and spread to a new one, beginning the infection cycle again. 
Indeed, transmission occurs most efficiently from hosts with cavitating mature granulomas [4]. How 
the shift between a granuloma supported by the apoptosis of macrophages and a cavitary granuloma 
occurs is not fully clear; however, it is clear that the necrosis of macrophages infected with Mtb is 
responsible for releasing intact bacteria into the tissue of the bronchial tree [4]. From within this 
medium, the mycobacteria can multiply and enter the airway to be aerosolized in cough droplets and 
spread readily to new hosts through proximal air [4]. This is called an active TB infection. Some 
people‘s immune defenses are overcome by Mtb later than others, which is why the bacteria may 
remain latent for years before an active disease state manifests. For individuals with latent TB there 
is a 5-10% risk each year that the latent state will develop into an active infection, and in HIV-TB 
coinfected individuals there is approximately a 50% lifetime risk of reactivation [3]. When drug 
treatment is not effectively applied or the Mtb causing the infection is resistant to treatment, TB 
remains contagious and also causes life-threatening complications like cavities in the lungs that bleed 
and can be infected with different bacteria, holes in the airways of the lungs, or blocked airways that 
strain breathing [3]. At this stage, active TB is simultaneously a serious danger to the infected 
individual‘s life and a threat to their community. 
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1.3 Challenges To Curing Tuberculosis 
Once an infection has begun, Mtb is very difficult to eliminate because of its persistent and 
diverse virulence factors, which continuously challenge the immune system‘s ability to clear the 
infection. In this way, Mtb creates niches in the body where it can persist in evading the immune 
system as it acquires nutrients and continues to grow. These Mtb-friendly niches combined with 
unique features of Mtb also give the bacteria an advantage when drug treatments are administered to 
clear the infection. For example, the signature feature of Mtb‘s cell wall is its high mycolic acid 
content, which provides intrinsic resistance to antibiotics [8]. The location of Mtb inside 
macrophages and within granulomas further reduces the accessibility of the bacteria to antibiotics. 
Other features of Mtb, like its efflux pumps or its ability to persist in a dormant state and develop 
phenotypic drug resistance, also challenge administered drug treatments.  
Although TB has been considered a treatable and curable disease because drugs capable of 
killing Mtb exist, even strains that are susceptible to these drugs remain so difficult to treat that 
stringent six- to nine-month courses of four-drug cocktails are required [5]. The small variety of drug 
treatment regimens available for TB, both active and latent, are limited in efficacy and difficult for 
the patient to maintain. Typical treatment recommendations for drug susceptible strains advise an 
initial two-month intensive regimen of isoniazid (INH), rifampicin (RIF), pyrazinamide, and 
ethambutol [5]. Afterwards, a four-month continuation phase with just INH and RIF is common for 
up to six-months for active infections, or a four to nine months for latent TB [9]. Every dose during 
these phases must be taken daily without fail to cure the patient, so doctors are frequently required 
to monitor patients directly to ensure compliance. Also, since these drugs are aggressive and 
prescribed for extended periods of time, treatment causes side effects that further discourage 
patients from completing the regimen. The high financial burden of completing treatment is an 
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additional barrier to curing Mtb infection even when it is susceptible to these first-line drug 
cocktails.  
1.3a An Emerging Threat: Drug Resistant Mtb  
The poor efficacy of current antibiotics and the noncompliance associated with their 
regimens are contributing to the advancement of drug resistant Mtb strains. Records indicate a 
significant increase in Mtb strains worldwide that are resistant to the front-line TB drugs. The WHO 
estimated in 2014 that 3.5% of newly acquired TB and 20.5% of previously treated TB cases are 
resistant to first-line drug treatments [5]. Classified by their level of resistance, Mtb causes Multi-
drug resistant TB (MDR-TB), eXtensively drug resistant TB (XDR-TB), and Totally drug-resistant 
TB (TDR-TB). MDR-TB is caused by Mtb strains resistant to the powerful activities of RIF and 
INH, and currently has a cure rate of only around 48% globally [5]. Approximately 480,000 people 
developed MDR-TB in 2013 [1]. Treatments for MDR-TB rely on second-line drugs, like 
fluoroquinolones and aminoglycosides, and last upwards of two years in many cases [5]. These 
second-line drugs are remarkably more toxic to the patient, less effective, and more expensive [5]. 
XDR-TB results from strains of Mtb that are additionally resistant to second-line drug treatments, 
and the strains that cause TDR-TB are entirely resistant to all available treatment options [10]. 
Patients infected with XDR- and TDR-TB face a bleak prognosis, and some postulate that the 
spread of these strains would result in a ―return to a pre-antibiotic era‖ [11]. Weak adherence to 
treatment courses and drug regimens that are incorrectly chosen or poor in quality are the central 
contributing factors to the emergence of drug resistant TB in individual patients [5].  
Mtb generally develops drug resistance in two ways, either genetic or phenotypic [5]. Genetic 
drug resistance arises when fixed genetic mutations occur in a particular strain of Mtb that disrupt 
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the ability of a drug compound to interfere with its target. For instance, spontaneous mutations may 
arise that modify the target and block drug binding, the target may become overexpressed, or a 
series of genetic changes may occur in concert within the bacteria to mediate drug resistance [5]. 
Phenotypic drug resistance to an antibiotic arises when Mtb in the host becomes transiently resistant 
without fixed genetic mutations occurring [5]. For example, Mtb replicating within macrophages are 
able to turn on efflux pumps that allow them to tolerate antibiotics by actively pumping the foreign 
compounds out of their cells [5]. Understandably, this contributes significantly to the long treatment 
periods required to cure patients of TB, which in turn contributes to an increase in opportunities for 
drug resistant strains to take hold.  
Considering the significant threat posed by TB and drug-resistant TB worldwide and the 
limited number of drug treatments available, it is important to discover new antibiotics that treat TB 
more effectively by acting against shrewdly selected targets. Current drugs inhibit general targets, like 
the synthesis of cell wall components or RNA and protein synthesis. By contrast, novel specific drug 
targets, like under-studied essential protein-protein interactions occurring within Mtb, have the 
potential to reveal antibiotic compounds that are both new and more effective at combatting drug-









CHAPTER TWO: DRUG DISCOVERY EFFORTS 
 The outlook on TB drug discovery is bolstered by extraordinary potential for the future, but 
currently the establishment of new TB treatments is still marked by slow progress and limited 
success. In fact, in 2012 bedaquiline became the first TB drug approved by the Food and Drug 
Administration in over forty years that kills Mtb through a novel mechanism of action [12]. Arguably 
the most significant aide to TB drug discovery has been knowledge of Mtb‘s entire genome 
sequence and the advances in understanding the molecular biology of Mtb. Considering that the 
majority of the genes encoded in Mtb still have unknown functions, there remain significant gains to 
be made both in unraveling the biology of Mtb and in exploring novel drug targets. This potential 
combined with the current gap in new TB drug candidates and the desperate need for novel TB 
drugs motivates us to engineer innovative drug discovery platforms that improve upon current TB 
drug discovery methods.  
2.1 Existing TB Drug Discovery Strategies and Their Problems  
 TB drug discovery and development today is a costly and time-consuming endeavor that 
requires investigators to take an interdisciplinary approach at each step of the process. The drug 
development pipeline can be broken down into two parts: early pharmaceutical research and late 
pharmaceutical research and development. Projects focused on the early stage of drug development 
aim to identify and validate targets and to identify and optimize lead compounds based on ―hits‖ 
identified for these targets during drug screens. Within this stage, two main strategies are commonly 
employed: target-based biochemical screening and whole-cell based screening [13]. Target-based 
screens are hypothesis-driven, analyzing the effects of a library of compounds on a purified target 
protein that is mechanistically relevant to pathogenesis. Meanwhile, whole-cell screens analyze the 
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ability of drug compounds to kill or inhibit a pathogenic phenotype of bacterial cells without 
focusing on a particular pathway. Target-based screens have traditionally proven problematic and 
unsuccessful because of their tendency to identify hits that are potent against the target of interest 
but that ultimately are not capable of eliminating bacterial growth [13]. This most commonly occurs 
because the compound cannot actually penetrate the bacterial cell, either in vitro or in vivo, or because 
the bacteria are capable of inducing efflux of the compound from effectively inhibiting its target 
inside the cell or from crossing the cell wall to begin with [12]. Whole-cell screening, by comparison, 
overcomes issues of cell-penetration and cell-efflux and has therefore been relatively successful as a 
strategy for TB drug discovery, making it the go-to method for identifying hits [12]. Through whole-
cell screening, investigators may identify hits for sensitive and accessible pathways that might not 
have been predictable targets, but this strategy still leaves room for improvement. Mainly, the 
efficiency of whole-cell screening is compromised because it requires that the target of the hit be 
identified retroactively in order to optimize the potency of the hit compound [12]. If identification 
of the hit‘s target takes a long time or is completely unsuccessful, this optimization process can be 
significantly delayed. Recent reviews also point out some informative patterns that have emerged as 
a result of extensive use of whole-cell screening over the past 5-10 years, which provide reason to 
think that moving beyond simple whole-cell screening has become necessary [12]. For instance, it 
has been observed that whole-cell screens performed by various groups exhibit redundancy, 
identifying hits that are structurally identical or nearly identical repeatedly [12]. This is likely due to 
the lack in diversity of the screening methods utilized and the compound libraries [12]. Additionally, 
whole-cell screening results exhibit redundancy in the mechanistic targets identified for various hits, 
most of which are proteins involved in the cell surface or bound to the cell membrane [12]. On the 
one hand, this is a positive aspect of simple whole-cell screening—the most accessible targets are the 
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first to be identified. However, to combat a disease as prone to drug resistance as TB, it is not 
enough to recycle the same targets and the hits for these targets redundantly. It would be remiss not 
to use knowledge recently gained about the molecular biology of Mtb to investigate the potential of 
other novel, sensitive targets by rethinking traditional screening methods. Specifically, methods that 
are capable of combining target-specificity and whole-cell screening to eliminate the main drawbacks 
of each of these methods alone are the ideal next step.   
2.1a Characteristics of an Ideal TB Drug Discovery Approach  
 An ideal TB drug screening method would focus on validated targets and would be 
performed on whole Mtb cells, with the option to perform the screen under relevant in vivo-like 
conditions.  Target-specific whole-cell screens of this sort are more likely to succeed in identifying 
hits that will translate to drug development because they ensure that the hit can penetrate the cells 
while also demonstrating that a given hit interferes with the desired target. This allows the efficacy of 
the lead compound to be optimized expediently and also more quickly provides information that 
may assist investigators to identify patterns that make particular target/hit combinations successful. 
Targets selected for these screens ought to be novel and known to be essential for Mtb‘s 
pathogenesis. Novelty becomes an increasingly important factor as treatments are sought to combat 
the spread of drug-resistant strains of Mtb. Re-examining old targets that are already at the crux of 
drug-resistant strains is not likely to produce new therapies that would be clinically effective long-
term, as these targets have already proven they can be readily mutated to the bacteria‘s advantage. 
An ideal drug discovery platform would also be well-adapted to high-throughput screening (HTS), 
with emphasis on optimizing the time, costs, and quality of the screen for lead discovery [13]. A high 
quality screen features few false positives and few false negatives, a chemically diverse and novel 
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screening library, high signal/noise ratio, and a Z‘-factor between 0.5 and 1 [13]. The Z‘-factor is a 
coefficient that defines the optimal window within which a particular assay‘s readout signal is 
statistically significant [14]. The Z‘-factor is used as an indicator of the quality of an assay, and it 
reflects the level of confidence with which the assay will be able to identify hits [14]. Other factors 
of an ideal assay include a relatively inexpensive and simple set up, an easily quantifiable, highly 
specific readout, and great versatility in the targets to which the screen can be applied. A screen 
meeting these standards would represent a promising step toward discovering novel drug therapies 
to treat TB.   
2.2 Protein-Protein Interaction-Based Drug Discovery: An Innovative Strategy 
 The significance and complexity of protein-protein interactions (PPIs) that are vital for 
regulating most of the biological processes in both prokaryotic and eukaryotic cells cannot be 
overstated. The ability of Mtb to evade immune defenses and to cause disease is intrinsically 
dependent on its unique network of protein-protein interactions. A variety of novel methods for 
studying PPIs have been applied across many species of bacteria to elucidate the mechanisms 
underlying vital processes like DNA replication, metabolism, and formation of enzyme complexes as 
well as virulence factors that interact with host cells. Knowledge of these mechanisms has driven the 
design of improved and novel treatments for diseases that result directly from specific cellular 
processes.  However, the PPIs that are critical for Mtb pathogenesis have not been explored in 
depth and are still very poorly understood. This gap in knowledge signifies vast potential because 
increased examination of essential Mtb PPIs would reveal important aspects of Mtb pathogenesis 
that could be exploited as specific drug targets. Inhibiting the formation and activity of critical 
protein complexes by targeting the interfaces between interacting proteins would represent a 
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promising yet underexploited avenue to address the urgent need for improved treatment options for 
TB. This approach is also highly compatible with the ideal target-specific whole-cell screen already 
described.  
 Discovering small molecules capable of interfering with PPIs was once viewed as far too 
challenging and was initially marked by very little success [15]. However, it has become increasingly 
evident that successfully targeting PPIs with small-molecules is a promising path to drug discovery. 
Over 40 PPIs relevant to various diseases have been successfully targeted with synthetic molecules, 
and several of the lead compounds identified have progressed to clinical trials [16]. The advances 
that have been made in specifically designing peptides and small molecules to interfere with certain 
PPIs will only continue to accelerate the efficacy of this approach. The progress made in targeting 
PPIs primarily came from the identification of ―hotspots‖ critical to the interactions of protein-
protein interfaces [16]. These hotspots are small subsets of the residues involved in the total, large 
protein-protein interfaces that contribute the most to the free energy of binding between the 
proteins [15]. The existence of hotspot regions refuted the concern that PPI interfaces could not be 
targeted by small molecules, when it was initially thought that large, flat contact surfaces between 
proteins were necessarily rigid and would not offer spots for small molecule binding [15]. Recent 
successes have demonstrated consistently that contact surfaces do provide conformationally-flexible 
cavities available to small molecules for tight binding and interference of PPI [15]. Concerns over 
the sheer lack of success of HTS applied to protein-protein interfaces have also been raised. But 
because empirical evidence has shown that HTS can successfully lead to valid hits against PPIs, it is 
important to consider that HTS‘s lack of success has likely been due to the libraries of compounds 
that are traditionally most readily available and most utilized for screening [15]. These libraries were 
often optimized for screens against traditional drug targets like G-protein-coupled receptors and 
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enzymes, while it has become clear that each PPI is distinct and the scaffolds that worked to unlock 
these traditional targets are unlikely to do the same for the unique interfaces that are critical for 
distinct PPIs [15]. A third common objection to PPI-based screening was the notion that small 
molecules are not capable of displacing protein partners effectively because native protein 
complexes have a higher affinity for one another. However, it has been demonstrated that under 
equilibrium conditions small molecule inhibitors can often be found to have an advantage over the 
natural protein partner, binding deep within the contact hotspot with high, drug-like efficiency [15]. 
Given the mounting evidence that PPIs can be successfully exploited for drug discovery, the 
incredible potential exploiting novel PPIs in Mtb holds, and the compatibility of PPI-based 
screening with the ideal TB drug discovery approach, pursuing the development of a drug screening 
platform that targets PPI is an innovative and favorable endeavor. 
2.2a Mycobacterial-Protein Fragment Complementation  
 Protein-fragment complementation (PFC) assays have been remarkably useful for studying 
PPI in a variety of biological systems. This utility led to the development of a method called 
Mycobacterial-Protein Fragment Complementation (M-PFC). The M-PFC assay uses a viability 
readout to assess whether two proteins interact in Mycobacterium smegmatis (Msm) which is utilized as a 
surrogate host in place of Mtb. This works by fusing the ―bait‖ protein to one domain of the split 
dihydrofolate reductase (DHFR-A) reporter and fusing the ―prey‖ protein to the other domain of 
the split DHFR reporter (DHFR-B) [17]. Each of the two plasmids containing the bait/DHFR A 
and prey/DHFR B elements are also resistant to kanamycin or hygromycin so Msm cells containing 
both plasmid inserts can be selected following transformation [17]. The two halves of DHFR 
protein are inactive when they are apart, but if the bait and prey proteins interact in Msm, the 
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DHFR halves are reconstituted into an active DHFR protein [17]. DHFR confers resistance to 
trimethoprim in Msm. Therefore, if the bait and the prey are positive for interaction, the bacteria 
survive when grown in the presence of trimethoprim (see Figure 1).  
 
Figure 1: Basics of M-PFC. A) Negative bait and prey interaction B) Bait and prey proteins that are positive for 
interaction, causing reconstitution of DHFR. Growth on trimethoprim results. 
To acquire a quantitative measure of PPI binding, cultures of the M-PFC Msm strains are incubated 
in the presence of TRIM. Afterwards, Alamar blue dye (resazurin) is used as a readout to reflect the 
viability of the bacteria in response to their exposure to trimethoprim. When bacterial growth 
occurs, the blue resazurin is reduced by the bacteria to a fluorescent pink color, the intensity of 
which can be readily quantified using a plate reader [17]. 
The M-PFC has also been translated to screen a variety of targets for compounds that are 
effective at preventing the targeted PPI from occurring in Mtb, killing the bacteria‘s virulence [17, 
18]. Effective compounds prevent the protein partners from interacting, so DHFR-A and DHFR-B 
are not reconstituted. Therefore, the bacteria cannot survive when grown in increasing 
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concentrations of trimethoprim, which is displayed by a lack of fluorescence upon incubation with 
resazurin (See Figure 2). Prior to the development of M-PFC, it was not possible to set up screens 
for inhibitors of PPI in Mtb because tools capable of reporting the interruption of PPI inside 
mycobacteria were not available [17]. Now the M-PFC assay is a highly versatile approach for 
screening for compounds that are active against specific PPI targets in a whole-cell context in 
mycobacteria. Thus, it is an ideal starting-point for developing an innovative TB drug screening 
platform based on PPI inhibition. Establishment of strains showing PPI of novel targets combined 
with fluorescent improvements to the M-PFC are critical to improving the quality and practicality of 
this platform.  
 
Figure 2: The Relation Between PPI, TRIM Resistance, and Resazurin Reduction in M-PFC Strains of Msm. 
The stronger the interaction between the protein partners of the M-PFC strain, the greater the reduction is of blue 




CHAPTER THREE: TB GYRASE AS A NOVEL TARGET OF THE M-PFC 
DRUG DISCOVERY SYSTEM 
3.1 The Role of TB Gyrase  
 TB gyrase is a well-studied and clinically validated target for TB drug discovery that plays a 
vital role in the bacterial cell. Like the topoisomerase enzymes found in other bacteria, TB gyrase is 
necessary to maintain the functionally required topology of the DNA molecules in Mtb [19]. During 
the processes of replication and transcription topoisomerase enzymes act to moderate the winding 
of DNA about itself, regulating the level of tension the DNA molecule experiences as a result of its 
double-stranded helical structure and closed circular domain in bacteria [19]. The type I 
topoisomerase family is able to cut one strand of the DNA at a time to reduce stress on the helix by 
passing it through a single-stranded break and reannealing it [20]. But type II topoisomerases act on 
both strands of DNA, cutting two strands to produce a double-stranded gap through which another 
portion of the duplex is passed and then reannealed [20]. Bacterial DNA gyrase is a type II 
topoisomerase that is present in all bacteria [20]. In Mtb, just two topoisomerase genes are present: 
DNA gyrase is the only Type II topoisomerase, and a homolog of the E. coli topoisomerase I gene is 
also encoded [20].  
 As the only available type II topoisomerase in Mtb, DNA gyrase introduces negative 
supercoils in the DNA, relaxes positive supercoiling, and moderates decatenation of replicated DNA 
[20]. The structure of the complete TB gyrase tetramer is not yet available; however, the structures 
and arrangements of components of the tetramer have been solved independently [21, 22]. Plus, the 
gyrase gene in E. coli and other bacteria and the gene in Mtb are sufficiently conserved so that it is 
reasonable to draw missing information about the structure and function of TB gyrase from facts 
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known about gyrase in other bacteria [23]. To form a series of gates through which DNA can be 
threaded, the enzyme forms a tetramer consisting of two A subunits and two B subunits, encoded 
by gyrA and gyrB respectively [20]. The opening and closing of these gates to break the DNA, pass 
another DNA segment through the break, and rejoin the break is coupled to ATP hydrolysis [24]. 
The breakage and reunion steps are catalyzed by the A subunit, while the B subunit contains the 
ATPase domain [20].  
The A protein‘s (GyrA) core features two dimer interfaces: the primary dimer interface and 
the head dimer interface [24]. It is believed that the N-terminal interface binds the DNA that will 
form the gate for strand passage, while the C-terminal domain of GyrA (GyrA-CTD) is thought to 
mediate changes in supercoiling by binding closely spaced segments of DNA and encouraging them 
to wrap around the protein in the required direction before reannealing takes place [20]. Studies of 
the full length GyrA reveal that the dimeric 59kDa core is flanked by the two pear-shaped GyrA-
CTD monomers [20]. Importantly, GyrA is capable of dimerizing and binding DNA in the absence 
of the B subunit, but for all of the gyrase reactions to take place both subunits must be present [19].  
The B protein (GyrB) features an ATPase site N-terminal domain, which dimerizes when 
bound to ATP [20]. The C-terminal domain of GyrB is responsible for interaction with the GyrA 
protein and its bound DNA [20]. Protein-protein interactions, recycling of the enzyme, and 
interaction of the transfer segment of the DNA with gyrase is dependent on the ATPase activity of 
GyrB [20].  
3.2 TB Gyrase A: A Worthwhile M-PFC Target 
 While investigating novel targets for the development of new classes of antibiotics is a valid 
and promising strategy in the search for new TB drugs, exploring targets like TB gyrase that are 
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already relatively well-understood and clinically validated also has its merits. This approach benefits 
greatly from the knowledge that any chemical inhibitors discovered against the target will 
successfully inhibit the growth of Mtb. Additionally, more strategic selection of the compounds that 
will be screened against the target can be performed. The specific sites of the target that have been 
most successfully targeted by old antibiotic compounds can be examined and used as a reference for 
generating new compounds that will interfere with the target site more effectively. A caveat to this 
method concerns antibiotic resistance. Generating new drugs by studying a target site that has 
previously been extensively exploited is not effective if Mtb has already developed drug-resistance 
mutations at that site. This can happen when Mtb has been exposed to previous classes of 
antibiotics that target the same site redundantly. Therefore, investigating a validated target site that 
also contains low levels of drug-resistance mutations in clinical isolates is advantageous.  
 The fluoroquinolones are a class of powerful antibiotics that bind to the DNA-gyrase 
complex and interfere with the enzyme‘s normal function, leading to the accumulation of double-
stranded fragments of DNA and the death of the treated bacteria [20]. Fluoroquinolones are capable 
of killing mycobacteria and have shown promise in reducing the length of TB treatment regimens 
[20]. These abilities have been strongly correlated with their inhibition of DNA gyrase [20]. 
Inhibiting DNA gyrase is an effective way to kill non-replicating, persistent mycobacteria, and older 
fluoroquinolones have been effective as part of treatment regimens for MDR-TB [20]. Additionally, 
levels of resistance to fluoroquinolones remain low in clinical isolates of Mtb, suggesting that Mtb‘s 
resistance to novel compounds that would act on DNA gyrase is desirably low [20]. Thus, TB gyrase 
is a valid and promising target for discovering new drugs to treat TB. Because fluoroquinolones are 
known to act on GyrA specifically, developing a drug screen capable of identifying compounds that 
disrupt the GyrA dimer is a worthwhile endeavor. While fluoroquinolones have been the most 
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effective existing compounds to target DNA gyrase thus far, the potential for exploring 
improvements to the spectrum, potency, and specificity of these drugs is becoming exhausted [23]. 
On the other hand, it remains clear that GyrA as a target holds significant potential for the 
development and discovery of new antibacterial compounds. Therefore, an M-PFC assay targeting 
GyrA, which could efficiently screen for novel compounds that disrupt the function of the GyrA 














CHAPTER FOUR: NOVEL FLUORESCENT IMPROVEMENTS TO THE 
CURRENT M-PFC DRUG SCREENING PLATFORM 
4.1 Fluorescent M-PFC  
 M-PFC has become a compelling method for pioneering the validation of new PPI in Mtb.   
Furthermore, this has led to the development of an M-PFC based drug screen for molecular 
inhibitors of these intriguing PPI. However, a drawback of the original M-PFC is its readout because 
it requires the addition of resazurin followed by an extended incubation before results can be 
collected. Necessarily adding exogenous reagents increases the time and cost of completing the M-
PFC assay, increases the likelihood of human error, and decreases the number of screens that can be 
completed per month. Ideally this additional step would be eliminated to make the M-PFC more 
amenable to HTS by increasing its efficiency and improving the reliability of the readout.  
 To eliminate the need for resazurin, an alternative fluorescent readout has already been 
tested for the M-PFC assay using the red-fluorescent protein mCherry. In this mCherry M-PFC 
system, an mCherry gene driven by a strong constitutive promoter was introduced on both the 
episomal and chromosomal plasmids that are used to construct the M-PFC assay. This changes the 
assay‘s readout so that rather than measuring the reduction of resazurin by bacteria surviving in 
increasing concentrations of TRIM, the fluorescence due to the constitutive production of mCherry 
by surviving bacteria is measured instead. As before, growth of the bacteria in higher concentrations 
of TRIM indicates the presence of the protein-protein interaction of interest, but the bacterial 
growth is detectable due to the innate fluorescence of the mCherry protein. This fluorescent signal 
can be conveniently read on a plate reader without the addition of any exogenous reagents. The 
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mCherry M-PFC represents a more streamlined approach for studying novel PPI and screening for 
inhibitors of these interactions in Mtb.  
4.2 Modifications to the Red-Fluorescent Protein mCherry  
 The study of bacterial pathogenesis benefits greatly from genetically encoded fluorescent 
proteins (FPs), which have served as the basis for versatile techniques for examining proteins and 
cells of interest, and have also been instrumental in examining these in the context of model hosts 
[25]. For example, fluorescence has been used for visualizing processes within live cells, reporting 
transcriptional and translational activity, and comparing characteristics of mutant cell types. 
Enhanced red-shifted fluorescent proteins (RFPs) have several advantages over FPs of other colors. 
Specifically, RFPs feature reduced autofluorescence, decreased phototoxicity, and reduced light-
scattering which make them superior for experiments where low background noise and high viability 
of cells is important [25]. Perhaps the greatest additional benefit of RFPs is that they are 
complementary to the use of other FPs—blue, cyan, green, or yellow, for instance—when 
multicolor applications are desired [26]. The most popular general-purpose RFP is mCherry because 
it possesses high photostability and a low maturation time, performs well when fused to other 
proteins, provides a high signal-to-noise ratio, and is monomeric and thus generally nontoxic to the 
cells expressing it [26]. Although it is not as bright as mStrawberry or tdTomato, two other FPs in its 
class, the other features of mCherry combined make it superior to brighter RFP variants [26].  
In our work with mycobacteria, mCherry has remained a reliable and useful fluorescent tool. 
Previous experiments have used mCherry as a reporter gene for assessing the results of reporter-
fusion constructs in Msm and Mtb. The use of mCherry to monitor the activity of mycobacterial 
promoters is ideal because it provides a direct fluorescent readout that reflects cues and timing 
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associated with gene regulation. Other projects have utilized mCherry for simple phenotypic drug 
screening, in which Msm and Mtb bacteria have mCherry integrated into their genome, these strains 
are grown, and the cells are treated with drugs. It was demonstrated that bacteria surviving a given 
compound grow and produce fluorescence, but those that are killed by the compound lack 
fluorescence. As discussed above, recently mCherry has also been successfully integrated into the 
assessment of protein-protein interactions as the reporter for an improved M-PFC assay. Therefore, 
advancements in the uses of mCherry that result from optimizing its fluorescent and spectral 
properties have the potential to improve fluorescent tools in a wide sense, and to impact the study 
of pathogenesis in mycobacteria significantly, too.  
4.2a Large Stokes Shift mCherry  
 A subclass of improved FPs are those that have been modified to feature a large Stokes shift 
(LSS). The Stokes shift of a given FP is defined as the difference in wavelength between the 
respective maximums of the excitation and emission spectra, as shown in Figure 3. An LSS FP 
distinctively exhibits a difference between these maxima of larger than 100nm [25]. Typically LSS 
RFPs have been utilized to increase the sensitivity and decrease the background of multicolor 
imaging applications like Förster resonance energy transfer (FRET), but the improved separation of 
the absorbance and emission maxima is potentially advantageous even for single-color imaging 
applications [25].  
 By characterizing the molecular networks that generate LSS fluorescence in LSSmKate, an 
RFP, Piatkevich et. al. successfully engineered a range of new LSS FPs, including LSSmCherry. Two 
point mutations were strategically introduced to the wild type mCherry gene, resulting in a serine at 
amino acid 158 and a glutamic acid at 160 [27]. These modifications were made to introduce support 
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for an excited-state proton transfer (ESPT) pathway analogous to those found in LSSmKate1 and 
LSSmKate2, shown to be responsible for the large Stokes shift of these proteins as well as several 
other LSS FPs [27]. Wild type mCherry exhibits an excitation maximum at 587nm and an emission 
maximum at 610nm, while LSSmCherry demonstrated a significantly shifted excitation maximum at 
456nm when produced in E. coli and purified [27]. Similar success occurred when this method was 
applied to generate LSS variants of a handful of other commonly used fluorescent proteins including 
mNeptune, mStrawberry, and mOrange using E. coli [27]. LSSmCherry has not yet been used for 
applications in mycobacteria, and generating this mutant holds the potential to increase the 
sensitivity of the assays that currently utilize mCherry readouts. This may prove particularly 
impactful for the mCherry M-PFC since increasing the sensitivity of this assay would decrease the 
likelihood that weakly interacting protein-protein pairs are overlooked. Additionally, when the 
mCherry M-PFC is applied to drug-screening, increasing the signal-to-noise ratio by upgrading the 
sensitivity of the readout is desirable.  
 
Figure 3: Definition of the Stokes Shift of a Fluorescent Protein. The difference between the peak of the excitation 
spectrum, shown in blue, and the peak of the emission spectrum, shown in red, defines the Stokes shift of a fluorescent 
protein. When this difference is larger than 100nm, the fluorescent protein is considered to have a large Stokes shift.  
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4.2b Bimolecular Protein Fragment Complementation and Split mCherry  
 While PFC assays utilizing split reporter enzymes like DHFR are widely accepted and 
reliable, the readouts of these assays have been uniquely improved by a subsequently developed 
method called bimolecular fluorescence complementation (BiFC). Rather than measuring the effect 
of a truncated enzyme‘s reconstitution (i.e. TRIM resistance conferred by DHFR), a BiFC assay 
relies on the reconstitution of a split fluorescent protein as its reporter [28]. The protein partners of 
interest are each fused to a non-fluorescent fragment of the FP, typically by a flexible glycine linker 
region [29]. When brought together by the interacting pair of proteins in vitro the FP reforms and 
generates a functional fluorophore [29].  Thus, BiFC assays provide a real-time fluorescent signal 
indicative of PPI in living cells. Not only does this feature allow visualization of the PPI, but it also 
creates a highly sensitive assay with minimum background because fluorescence is not recovered 
without interaction of the two proteins of interest [29]. Thus, BiFC is often advantageous compared 
to other fluorescence-based visualization techniques, particularly FRET. While FRET is more 
desirable than BiFC for capturing dynamic, instantaneous interactions of protein partners, it is less 
sensitive than BiFC because it only reflects the small number of partners that happen to interact 
with each other at a given moment [29]. This often means the protein partners of interest ought to 
be overexpressed to increase the sensitivity of a FRET assay, which is importantly not required for 
BiFC [30]. Additionally, the construction of the assay and gathering of data for FRET is more 
involved than for BiFC [29]. FRET also requires that the interacting partners be located closer 
together than BiFC, increasing the likelihood FRET will miss some PPI occurring in 
macromolecular complexes that BiFC would not [29]. Even when visualization of the protein-
protein interaction is not the primary goal, BiFC remains advantageous over enzyme-based PFC 
readouts because it removes the necessity of treating cells with exogenous reagents, like resazurin in 
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the M-PFC. Removing this step is more efficient in terms of cost, time, and error-reduction while 
increasing assay sensitivity.  
Although the recently developed mCherry M-PFC does reflect PPI with a fluorescent 
readout, this fluorescence is importantly not a direct product of the proteins of interest fusing 
together. It is instead an indirect measure of PPI that reports the viability of the bacteria when 
exposed to various concentrations of TRIM. This report is then used to infer that the PPI of interest 
is present because, for the bacteria to survive in TRIM, the PPI must have facilitated reconstitution 
and function of the DHFR enzyme. As a result, the fluorescent M-PFC is less sensitive and less 
specific than a mycobacteria-compatible BiFC assay would likely be and it does not leave potential 
for visualization of the PPI itself. BiFC also holds more promise for studying multiple PPI at once 
than the fluorescent M-PFC does. Not only is it simpler to construct a multicolor screen to study 
multiple PPI occurring simultaneously within a single cell using BiFC, the information available 
about each partnership from such a screen would be more detailed and accurate since the readout is 
direct. These advantages become increasingly important when a given PPI assay is translated to HTS 
efforts, where easily quantified BiFC signals increase the efficacy of cell-based HTS.  
For over a decade, BiFC has been successfully applied to detect PPI in a variety of species of 
living cells using a variety of fluorescent colors. Large-scale BiFC screens for specific PPIs in yeast, 
plant, mammalian cells, and even for interactions occurring between proteins from different species 
have been achieved using split yellow, cyan, green, and red FPs [29]. The development of split RFP 
variants was of particular interest after yellow and cyan variants were introduced since RFPs 
extended the range of available wavelengths for BiFC assays, opening up more potential for 
multicolor assay construction [28]. Multicolor BiFC assays are performed to visualize multiple PPI 
simultaneously in the same cell. They are constructed by fusing multiple split fluorescent proteins, 
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which must feature sufficiently different spectral properties, to different pairs of protein partners 
[31]. The results of a multicolor BiFC assay allow useful analysis of the relative distribution of 
multiple PPI in the same cell [31].  
Split mCherry has been the most reliable of the RFP variants applied to BiFC, as it was 
demonstrated that an mCherry-based BiFC could be used to visualize both dimerization of EGFP 
and interaction of human p53 with SV40 large T antigen in Vero cells [29, 32]. Collectively, these 
BiFC successes have supplied knowledge about novel protein interactions and have stimulated drug 
development efforts. Specifically, HTS for small molecule inhibitors of PPIs using cell-based BiFC 
assays have also been validated in studies of HIV, cancer, and influenza A [29]. Interest in BiFC 
assays like these has increased because they combine uncovering deeper knowledge about the 
mechanisms of action of any identified inhibitors with the advantages of whole cell screening. 
Constructing a BiFC assay for use in Mtb with a novel PPI target would undoubtedly be an excellent 
tool not only for studying novel protein-protein interactions but also for discovering new 










CHAPTER FIVE: SPECIFIC AIMS 
 This project‘s focus is to engineer and evaluate three plausible improvements to the tools we 
currently use when evaluating PPI in Mtb. If these aims are successful, we will have a new PPI assay 
for HTS and improved fluorescent tools to enhance our PPI screen in Mtb and to bolster our drug 
screening capabilities.  
5.1 Aim 1: TB Gyrase A and the Fluorescent M-PFC   
 The TB gyrase complex is a validated and promising target for drug discovery in Mtb. 
Because of its links to fluoroquinolone activity, the GyrA dimer component of the complex is of 
particular interest. Thus, the GyrA dimer was selected as a target of the M-PFC and subsequent 
improvements to the M-PFC. The specific goals of this portion of the project are as follows: 
Aim 1.1: Create GyrA/GyrA M-PFC strains and validate the interaction of the GyrA/GyrA protein partners.  
 An M-PFC assay that can detect the interaction of the GyrA dimer will be created using 
genetic engineering techniques. Then, this GyrA/GyrA M-PFC will be used to confirm that GyrA 
partners with itself independently of the GyrB dimer, as supported by the literature. Following this, 
the relative strength of the GyrA dimer interaction will be characterized using the M-PFC.     
Aim 1.2: Enhance the GyrA /GyrA M-PFC by generating a GFP-based fluorescent GyrA/GyrA M-PFC.  
 After confirming that the GyrA/GyrA M-PFC demonstrates significant interaction between 
the GyrA partners, the assay will be simplified and improved by replacing the current dye-based 
readout with a GFP-based fluorescent readout. This will not only increase the quality of the assay, 
decrease the time required to complete the assay, and decrease the costs associated with running the 
assay, it will also improve the assay‘s applicability to drug screening in the future. 
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5.2 Aim 2: LSS mCherry 
 The unique spectral properties of LSS FPs can be used to increase the sensitivity of FP-
based assays. Substituting certain amino acids in wild type mCherry results in a large Stokes shifted 
mutant of mCherry. Because mCherry is the basis of the readout of many of our assays, including 
one version of the fluorescent M-PFC, generating an LSS mCherry is desirable.  
Aim 2.1: Generate an LSS mCherry strain of Msm.  
 Two amino acid substitutions will be made within the wild type mCherry gene to generate 
LSS mCherry. The LSS mCherry will be expressed constitutively in wild type Msm on an episomal 
plasmid.  
Aim 2.2: Investigate the spectral properties of LSS mCherry expressed in Msm.  
The characteristics of wild type mCherry will be compared to those expected of LSS 
mCherry. It is expected that the peak excitation wavelength will shift from 595nm in WT mCherry 
to 456nm in LSS mCherry.  
5.3 Aim 3 Focus: The Split mCherry BiFC 
 While the M-PFC and fluorescent M-PFC assays work reliably for detecting PPI, their main 
weakness is that they feature an indirect readout. This decreases the sensitivity and specificity of the 
assay while also limiting its range of potential applications. It has been shown that mCherry is 
compatible with the construction of a BiFC assay in Vero cells, but this tool has not yet been 
demonstrated in mycobacteria. Because BiFC has the potential to significantly enhance our ability to 
study specific PPI in a direct and specific manner, we will work to engineer a functional BiFC in 
Msm.        
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Aim 3.1: Generate split mCherry BiFC strains with protein partners known to interact strongly in Msm.  
 To demonstrate proof-of-concept of the mCherry BiFC in Msm, the protein partners will be 
selected based on the strength of their interaction and their compatibility with the known 
requirements for constructing an mCherry-based BiFC. Multiple mCherry BiFC strains of Msm 
featuring different partners will be created to determine whether the reconstitution of mCherry can 
occur in Msm.      
Aim 3.2: Characterize the properties of the mCherry BiFC strains and optimize the BiFC assay for studying PPI.  
 The mCherry BiFC strains will be assayed under various conditions mimicking those that 
have been optimal in other BiFC studies. An optimized procedure for performing the mCherry 
BiFC assay will be established so that this assay can be applied to studying other PPI or extended to 









 CHAPTER SIX: METHODS 
6.1 Bacterial Cell Culture 
 In the following experiments, NEB 10-Beta Competent Escherichia coli High Efficiency (E. 
coli) and Mycobacterium smegmatis mc2155 (Msm) were used [33]. E. coli were needed to host 
recombinant DNA constructs, to amplify DNA for standard cloning procedures, and to produce 
plasmid DNA for transformations into Msm. Msm was selected as a surrogate host in place of Mtb 
for these experiments because it is non-pathogenic and can be handled safely in BSL-2 conditions 
while still exhibiting most of the relevant qualities of Mtb, it grows robustly after only two days of 
incubation, and it readily expresses Mtb-exclusive genes that are G+C rich. Msm was used as a host 
to express M-PFC constructs, the LSS mCherry protein, and BiFC constructs.  
 E. coli cultures consisted of lysogeny broth (LB) and different concentrations of selective 
antibiotics, depending on the plasmids that were transformed into the bacteria. When constructs 
were built from plasmids pUAB100 or pUAB300, hygromycin B (Hyg) was used at 250 μg/mL. For 
constructs derived from plasmids pUAB200 or pUAB400, kanamycin (Kan) was used at 50 μg/mL. 
These cultures were routinely grown at 37°C in a culture tube overnight at a volume of 5mL while 
shaking at 250 revolutions per minute (rpm).   
 Msm cultures consisted of LB broth plus 0.05% polysorbate 80, referred to as Tween 80 (LB 
Tw broth) and lower concentrations of the selective antibiotics than those used for E. coli cultures. 
For pUAB100 and pUAB300 constructs, the Hyg concentration was reduced to 50 μg/mL. When 
selection for pUAB200 and pUAB400 was needed, 25 μg/mL of Kan was used. Standard Msm 
cultures were incubated at 37°C for three days while shaking at 40 rpm.  
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6.2 Aim 1 Methodology 
6.2a M-PFC Overview 
Four types of base plasmids were used in this project to construct the M-PFC assay: 
pUAB100, pUAB300, pUAB200, and pUAB400. The Hsp60 promoter region included on both 
plasmids is a constitutive promoter region that drives strong expression of the genes that follow it. 
The oriM region of pUAB 300 is an origin of replication that is included so that the plasmid can 
replicate in the cytoplasm of Msm. On pUAB 400, the Int region denotes an integration segment 
that causes the plasmid to integrate into the chromosomal DNA of Msm upon transformation. The 
Hyg and Kan resistance genes are included on pUAB 300 and pUAB 400 respectively so that 
antibiotic selection for the presence of these plasmids can occur. See Figure 4 for details. When 
transformed into Msm, the pUAB100/300 plasmids are retained and replicated as episomal 
plasmids, containing genes for the Protein Partner 2 (PP2) and DHFR B proteins. By contrast, the 
pUAB200/400 plasmids integrate within the chromosomal DNA of Msm upon transformation, 
containing genes for the Protein Partner 1 (PP1) and DHFR A proteins. pUAB200/400 are suicide 
plasmids that lack a mycobacterial origin of replication. In order to retain them following 
transformation, they must integrate within the chromosome of Msm via recombination at the phage-
derived Integrase (Int) site (See figure 4). One episomal plasmid (pUAB100 or pUAB300) can be 
transformed with one chromosomal plasmid (pUAB200 or pUAB400) into Msm at a time to 
generate a complete M-PFC strain. To confer selectivity during the genetic engineering process, 
these sets of plasmids also contain antibiotic resistance genes. Plasmids pUAB100/300 contain a 
gene for Hyg resistance and pUAB200/400 contain a gene for Kan resistance (See Figure 4). First 
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genetic engineering was used to insert the GyrA gene into base plasmids 300 and 400, in the position 
of PP1 and PP2. The details of the genetic engineering process can be found below. 
 
Figure 4: M-PFC Base Plasmids. Completed M-PFC strains of Msm contain one episomal plasmid (pUAB 100 or 
pUAB300) and one plasmid that integrates into the chromosome (pUAB 200 or pUAB 400). Before they can be 
transformed into Msm, these plasmids must be genetically engineered to contain the target protein partners and then 
they must be amplified in E. coli.  
The resulting constructs were transformed into E. coli and grown on LB plates containing their 
respective antibiotics to select for the bacteria containing the desired plasmid construct. Once it was 
confirmed that a certain colony of E. coli contained the target construct, these E. coli were used to 
produce copies of the plasmid for transformation into Msm. Antibiotic resistance was used to 
confirm the transformation of both the episomal and the chromosomal M-PFC plasmid into Msm, 
and then cultures of the complete M-PFC Msm strains, along with the necessary control strains, 
were grown for use in the M-PFC assay. The M-PFC assay measured the presence of PPI through a 
viability readout that reflects the reconstitution of DHFR due to positive PPI. When the bacteria in 
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a given column were positive for PPI, the bacteria survived in the presence of increasing 
concentrations of TRIM and were able to reduce Alamar Blue dye to a pink fluorescent color. When 
a lack of PPI was present in the bacteria, they were unable to survive in TRIM due to a non-
functional DHFR enzyme, and as a result the Alamar Blue dye remained blue (See Figure 2). Further 
details about these methods are explained in the following sections, and an overview of the entire 
method is shown in Figure 5 below. 
 
Figure 5: Overview of the M-PFC Assay. Genetic engineering is used to construct a pair of plasmids, each containing 
a protein partner connected to a DHFR fragment via a glycine linker. These plasmids are transformed together into 
Msm and the resulting M-PFC strain is grown on selective media. Cultures of the M-PFC strain and the necessary 
control strains are grown. The M-PFC assay is set up by adding the Msm strains plus the dilutions of TRIM to the plate, 
incubating them together for at least 48 hours, and then adding Alamar Blue dye to the wells. After a four hour 
incubation with the dye, the plate is read in a fluorescent plate reader, and quantitative data about the relative strength of 
the PPI is gathered based on how pink the dye becomes. 
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6.2b Creation of M-PFC Strains to Monitor GyrA/GyrA Interaction 
 Genetic engineering followed by transformation into Msm was used to create the M-PFC 
strains. These strains were later applied to the M-PFC assay to study the TB GyrA/GyrA PPI. To 
generate these strains, first the plasmids for the M-PFC assay were constructed using PCR followed 
by a method called FastCloning. Compared to traditional cloning methods, FastCloning is 
advantageous because it does not require gel purification, restriction digestion, or ligation [34, 35]. 
Because of this, the efficiency of cloning experiments was accelerated and the design of possible 
plasmid constructs was more flexible. 
 PCR and FastCloning 
To insert a new gene into a base plasmid, the original plasmid (the ‗vector‘) and the target 
gene fragment (the ‗insert‘) were amplified using Polymerase Chain Reaction (PCR). PCR is a 
technique used to logarithmically amplify a targeted segment of DNA, which in the case of 
FastCloning must include both the vector and the insert DNA. Specific forward and reverse primers 
are designed to flank the targeted DNA, causing many copies to be made of the desired DNA, 
compared to the original DNA. Due to the primer design, the ends of both the replicated vector and 
the insert DNA contained complementary overhangs of ~10-15 base pairs. The complementary 
overhangs allowed the vector and insert DNA to anneal together, fusing the new gene to its 
insertion site on the vector during the FastCloning reaction that followed. To ensure that the parent 
strands of DNA were degraded after they served their function as templates in the PCR reaction, a 
restriction enzyme called Dpn1 was added to digest methylated DNA while leaving the 
unmethylated vector and insert products of PCR unaffected. Products of the PCR reaction were 
analyzed by agarose gel electrophoresis on a 1% gel alongside a GeneRuler 1 kb DNA ladder to 
separate the DNA products based on their size and thereby verify the presence of the desired vector 
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and insert products. Figure 6 depicts an example of an agarose gel used for this purpose. Specific 
details of the PCR reaction used to amplify the vector and inserts are covered in the next paragraph.  
 
Figure 6: An Agarose Gel Confirming the Presence of PCR Products of Different Sizes. Lanes 1 and 2 contain 
fragments of ~2,500 base pairs amplified via PCR from template DNA. Lanes 3 and 4 contain different fragments of 
~2, 000 base pairs also amplified by PCR. The presence of these distinct fragments can clearly be distinguished by 
running PCR products alongside the 1kb ladder on the agarose gel.  
During a PCR reaction, several temperature-dependent steps are followed to utilize the 
primers needed to amplify the DNA. First, the template DNA gets denatured so that the 
complementary strands of DNA begin to separate and the added polymerase enzyme is activated. A 
secondary denaturing step follows, in which denaturation of the DNA segment in continues so that 
the hydrogen bonds holding base pairs together are compromised in the regions where the primers 
will anneal. Then the temperature is shifted to begin an annealing phase in which the primers 
hybridize with the parent DNA. The ideal annealing temperature depends on the particular primers 
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being used. Next, the extension phase begins with another shift in temperature that favors the 
function of the DNA polymerase enzyme that is selected for the reaction. In this case, the Phusion® 
enzyme was used. The polymerase enzyme is responsible for assembling the replicated strands of 
DNA using the parent strand as a template. The secondary denaturation, annealing, and extension 
steps are repeated twenty times to cause logarithmic amplification of the target segment, resulting in 
many more copies of the segment DNA than the template DNA. To complete the PCR reaction, a 
final extension step is included to allow any incomplete DNA products to finish the reaction. To 
generate these temperature phases and to ensure correct denaturation, annealing, and extension 
times, PCR reactions were run in a BioRad thermocycler following a set Phusion®-specific protocol. 
See Table 1 for an example of a typical PCR reaction cycle. The annealing temperature was 
determined based on the melting temperature of the primers used in a given reaction. The primers 
themselves were designed using a program called ―ApE – A plasmid Editor,‖ combined with 
sequences gathered from online Mycobacterial DNA databases, like ―MycoDB – xBASE –‖ [36]. 
Table 2 indicates the names of the primers used to construct the GyrA/GyrA M-PFC assay and 
their sequences. To set up a PCR reaction the protocol ―PCR Protocol for Phusion® High-Fidelity 
DNA Polymerase (M0530),‖ by New England BioLabs was followed [37]. A standard 25μL PCR 
reaction contains 1uL of template DNA (~10-20 ng/μL), 1μL of forward primer (100 ng/L), 1μL of 
reverse primer (100 ng/μL), 5μL of 5x GC Buffer, 0.5μL of 10mM deoxynucluotide (dNTP), 
0.25μL of Phusion® Enzyme, and 16.25μL of DNAse free water.  
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Table 1: A Typical PCR Reaction Cycle 
 
Table 2: Primers Used to Construct the GyrA/GyrA M-PFC Assay 
 
Upon affirming the presence of the desired PCR products, the vector and insert were 
FastCloned with one another. First, varying ratios of insert and vector PCR products were mixed 
together. Typically three ratios were used to find the concentration of insert:vector that was most 
efficient for a given fusion of insert with vector. Usually, three insert to vector ratios (4:1, 1:1, and 
1:4) were added to three tubes containing a total volume of 8 μL of PCR product in each tube. To 
these tubes 1.5μL Dpn1 enzyme was added and then the reaction was incubated at 37°C for two 
hours to catalyze the complete digestion of the methylated, parental DNA. If the correct ratio of 
insert to vector DNA was present, the result of FastCloning was a fully assembled vector and insert 
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combination. If the correct vector and insert were not assembled, the transformation into E. coli 
would not result in colony growth on the selective media.  Following the FastCloning reaction, the 
resulting plasmids were transformed into E. coli so antibiotic selection, colony screening, and 
sequencing could be used to confirm the desired plasmids had been constructed. Figure 7 details the 
step-by-step procedure of FastCloning.  
 
Figure 7: The FastCloning Process. A) Vector amplification via PCR with vector-specific primers. B) Fragment 
amplification via PCR with fragment-specific primers containing overhangs that are complementary to the amplified 
vector. C) Vector and fragment products are mixed in various ratios and exposed to Dpn1 to digest parental DNA. The 
remaining products begin to fuse at their complementary regions. D) The gene of interest is completely fused with the 
vector by the end of the incubation. E) The FastCloning product is transformed into E. coli.  
 
Transformation into E. coli, Colony Screening, and Sequencing 
To amplify the plasmids produced by the FastCloning reaction, the reaction products were 
transformed into E. coli according to the ―NEB 10-beta Competent E. coli (High Efficiency)‖ 
protocol, distributed by the manufacturer [33]. Some modifications were made to this protocol. A 
50μL aliquot of 10-beta Competent (cc.) E. coli was thawed, and the aliquot was split into thirds so 
that a total of 16.5μL of 10-beta cc. E. coli were present in each tube. Three tubes were needed for 
the three ratios of insert:vector. Usually 2μL of the FastCloning product (between 1pg and 100ng 
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DNA) was added per tube of E. coli and the tubes of E. coli were lightly flicked to distribute the 
DNA among them. The E. coli were incubated on ice for 30 minutes, and then they were heat 
shocked at 42°C for 30 seconds. Following heat shocking the cells were iced for 5 minutes, after 
which 200μL of Super Optimal broth with Catabolite repression (SOC) was added to each tube. The 
cells were placed in a 37°C incubator and shaken at 250rpm for an hour to recover. Then, 100μL of 
the SOC/E. coli suspension from each tube was plated on LB agar plates containing selective 
antibiotics (either Kan at a concentration of 50μg/mL or Hyg at a concentration of 150μg/mL) for 
the plasmid being transformed. The plated cells were incubated overnight at 37°C overnight, and 
colonies present on the plates were observed the next day. If colonies were present, then a colony 
PCR screening protocol was used to verify that the vector in fact contained the insert. To screen the 
colonies, the bacteria were lysed to extract their DNA, which was used in a PCR reaction with 
primers for the insert region to verify the insert‘s presence. These were the same primers that were 
used to amplify the insert from the parental DNA. Lysis of the bacteria was achieved by picking an 
isolated colony on a plate, adding the colony to a tube containing 20μL of deionized water, and then 
boiling the tube at 100°C for 5 minutes. To pellet the bacterial debris and leave the DNA in the 
supernatant, the tube was centrifuged at 13,000 rpm for 2 minutes. From the supernatant, 2μL was 
used as the DNA template in the typical PCR reaction previously described. When multiple colonies 
were screened at one time, the colonies were labeled on the plate before they were picked so they 
could be identified for making cultures. A 1% agarose gel electrophoresis process was used to verify 
that the size of the colony PCR product matched the size expected for the insert. Figure 8 
demonstrates an example of an agarose gel used for colony PCR screening.  
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Figure 8: An Agarose Gel Used During Colony PCR Screening. FastCloning products are transformed into E. coli 
and colonies are grown on selective media. DNA is isolated from these colonies and PCR is run with primers that 
amplify the fragment that was inserted into the vector. If a colony contains the target plasmid, then the PCR product will 
be the size of the intended fragment on an agarose gel. Lanes 2-5 on this gel are positive for the target plasmid, while 
lanes 1 and 6-8 are negative. 
In preparation for sequencing, E. coli colonies that were identified as positive through the 
colony screening process were picked and grown in 5mL overnight cultures to amplify the plasmid 
containing the desired insert.  An alkaline lysis protocol, along with the EconoSpin™ Spin Column 
for DNA from Epoch Life Science Inc., was used to extract the amplified DNA from the E. coli 
cells. Then a Nanodrop spectrophotometer was used to measure the concentration of the prepared 
DNA. To make certain that the DNA contained the target vector and insert, the prepared DNA was 
sequenced by Genewiz Inc. preceding transformation into Msm. The raw sequence data was 
analyzed using APE and in silico sequence models of the target plasmid constructs. Sequence data 
was aligned with the model sequences. DNA from a particular colony was positive when its 
sequence data matched the model sequence exactly. 
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 Transformation into Msm 
Using the genetic engineering techniques described above, the necessary pair of GyrA M-
PFC plasmids were constructed. Figure 9 displays the specific arrangements of the GyrA, DHFR, 
and glycine linker regions relative to one another on the plasmids that were constructed for this 
experiment. The final step needed to generate the GyrA/GyrA M-PFC strains was transformation 
of the constructed plasmids into Msm. The cell membrane of competent Msm cells was altered by 
electroporation, which exposes the cells to an electric field that increases the permeability of the 
membrane, facilitating the intake of the constructed plasmids. The plasmids were transformed into 
Msm individually to generate M-PFC control strains, and also together to generate M-PFC test 
strains. To perform an electroporation, a 100μL aliquot of wild type electro-competent Msm was 
thawed for ten minutes on ice. Without exceeding a volume of 4μL, between 200 and 500ng of the 
prepared DNA was added to the Msm cells and the cells were transferred into an electroporation 
cuvette. In the BioRad Gene Pulse X machine, the cuvette was exposed to 2,500 V (volts), 25 μF 
(capacitance), and 1,000 Ω (resistance). The cells were combined with 250μL LB Tw broth and 
transferred to a 2mL screw cap conical tube. For four hours the cells were incubated at 37°C and 
shaken at 40 rpm. Following this recovery period, 20μL and 100μL of the cells were each plated on 
LB agar plates containing appropriate antibiotics for selection. To determine that both plasmids 
were successfully transformed into Msm together, the cells were plated on double selection (Kan 
and Hyg) LB agar plates. Confirmed M-PFC strains were resistant to both Kan and Hyg, conferred 
by the antibiotic resistance genes of the two incorporated pUAB plasmids. Once transformed into 
Msm, the GyrA fused to each half of DHFR were expressed in the cells and the resulting 
GyrA/GyrA homodimer could be observed through the M-PFC assay.  
 43 
 
Figure 9: Plasmids Designed for the GyrA/GyrA M-PFC Assay. 
 
6.2c M-PFC Assay 
 For this project the M-PFC assay was performed to study the PPI between the GyrA 
homodimer using the GyrA/GyrA M-PFC Msm strain, which contained both GyrA_pUAB300 and 
GyrA_pUAB400. Negative and positive control strains were also used alongside the M-PFC strain. 
The controls included strains that contained GyrA_pUAB300 alone, GyrA_pUAB400 alone, and 
DosR_pUAB100+DosR_pUAB200. The GyrA_300 and GyrA_400 strains contain only one half of 
the DHFR protein linked to GyrA and serve as negative controls because no reconstitution of 
DHFR A and DHFR B can occur in either of these. The DosR_100+DosR_200 strain serves as a 
positive control because in previous M-PFC experiments it demonstrated moderately strong PPI 
[38]. To set up an M-PFC assay, cultures of each strain were diluted to a starting optical density of 
0.5. Then serial tenfold dilutions were performed to reduce the optical density of the cultures to 
0.0005. Next, 135μL of the cultures were added to their assigned positions in a 96 microwell plate. A 
row of wells containing LB Tw and no bacteria was included as a negative control. Then 15μL of 
two fold dilutions of TRIM from 200μg/uL to 1.56μg/uL were added to their assigned wells and 
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mixed with the cultures in those wells respectively. Using a gradient of TRIM reveals the relative 
strength of the PPI of interest. Initially, the gradient used ranges from 200μg/uL to 6.25μg/uL, but 
sometimes it is necessary to decrease the spread of the gradient to 50μg/uL-1.56μg/uL so that the 
relative strength of weaker PPI can be more accurately determined. The higher the TRIM 
concentration needed to inhibit the growth of the bacteria is, the stronger the PPI. Wells containing 
15uL of water in place of TRIM (0μg/uL TRIM) were included as controls. In a typical Alamar Blue 
assay, after the plate was set up it was incubated at 37°C for 48 hours. However, based on 
optimization experiments previously performed in our lab, this incubation was extended to five days 
for the standard GyrA/GyrA M-PFC. Following the incubation of the strains with TRIM, 15uL of 
Alamar Blue dye was added to every well. During this project, Resazurin (1X) dye was substituted 
for commercial Alamar Blue dye to reduce the cost of the assay. As previously described, the Alamar 
Blue/Resazurin dye is used as an indicator of bacterial survival and growth in the presence of TRIM 
in the M-PFC assay [17]. Growing bacteria actively respire and reduce the blue Resazurin dye to 
Resorufin, which is pink and fluorescent [39]. It takes four hours of incubation at 37°C after the 
Resazurin is added for it to be adequately reduced by the bacteria. At this point the distinction 
between the Resazurin wells, which contain dead bacteria, and the Resorufin wells, which contain 
growing bacteria, can be detected using a fluorescence plate reader, set for an excitation wavelength 
of 530nm and absorbing an emission wavelength at 590nm. The ―blank‖ wells used in this 
experiment contained only LB Tw broth without bacteria, water in place of TRIM, and Resazurin 
dye. These wells served as a control to determine the level of nonspecific signal generated by media 
interference, and the signals acquired from the rest of the plate were scaled to reflect this 
interference. The blank wells also served as indicators of contamination on the plate, in which case 
the assay was repeated.  
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 The additional time, cost, and handling associated with the necessary addition of Resazurin 
in the traditional M-PFC assay is the biggest weakness of this method. Therefore, a fluorescent 
readout was designed and implemented to improve the quality of the M-PFC assay. With this 
improvement, the assay could be readily applied to drug screening, specifically HTS.  
6.2d Fluorescent M-PFC Assay   
 A fluorescent M-PFC was developed to eliminate the need to add dye during the M-PFC 
assay while retaining the ability to detect relative TRIM resistance, and therefore relative strength of 
PPI in M-PFC strains of Msm. The fluorescent M-PFC assay was created by FastCloning the 
mycobacteria codon-optimized green fluorescent protein (GFP) gene onto both of the M-PFC 
plasmids. GFP attached to the Hsp60 promoter was PCR amplified off of pvvRG (a plasmid 
containing mCherry and the Hsp60 promoter:GFP cassette) for insertion into pUAB 300_GyrA, 
and off of pUAB400_GFP for insertion into pUAB 400_GyrA. The primers used for these 
FastCloning reactions can be found in Table 3. Before the fluorescent M-PFC is run, levels of 
fluorescence of the possible GFP strains were compared by transforming the fluorescent 
chromosomal M-PFC plasmid alone, the fluorescent episomal M-PFC plasmid alone, and both the 
fluoresenct chromosomal and episomal M-PFC plasmids together into Msm. Once a configuration 
producing sufficient green fluorescence is acquired, the GFP GyrA/GyrA M-PFC assay can be run.  
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Table 3: Primers Used to Construct the GFP GyrA/GyrA M-PFC Plasmids  
 
 The GFP M-PFC assay should be compared to the original M-PFC assay using the 
Resazurin readout to determine whether the fluorescent M-PFC demonstrates comparable or better 
quality. Using cultures of the same OD, consistent concentrations of TRIM, the same total volume 
in the microwells, and identical incubation time and temperature, the assays would be run side by 
side and compared for sensitivity and reproducibility.  
6.3 Aim 2 Methodology 
6.3a Making LSS Mutations to Wild Type mCherry  
 Two mutations to the WT mCherry gene were previously identified to generate the LSS 
mCherry protein in E. coli [27]. To reproduce this modification and to examine its use in Msm, the 
same alterations were made to the mycobacterial-optimized mCherry gene. The effects of these 
alterations were then analyzed in Msm to determine whether a functional LSS mCherry protein had 
been generated.  
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 A method called ‗Round the Horn Site-Directed Mutagenesis (RTHM) was used to make the 
following alterations to the WT mCherry gene from pvvRG: at base pair 497of mCherry a T was 
replaced with a G and at base pair 502 a C was replaced with a G. These specific point mutations 
were selected to replace amino acid 158E with 158S and amino acid 160G with 160E according to 
codons optimal in mycobacteria. These specific amino acid replacements were selected to generate a 
certain excited-state proton transfer (ESPT) pathway that is believed to be the cause of the unique 
properties of related LSS FPs [27].  
RTHM is a PCR-based method in which one or both of the forward and reverse primers can 
contain mutation(s). Primers are designed so that the mutation is present near the 5‘ end, while the 
rest of the primer through the 3‘ end matches the parent plasmid to form a readily-annealing 
portion. During initial PCR cycles, the forward and reverse primers anneal to the parent plasmid and 
the DNA template is copied to form a linear version of the template with the mutation(s) introduced 
at the primer sites. For the rest of the PCR cycles, the linear DNA containing the mutation(s) is 
copied. Compared to other site-directed mutagenesis procedures, RTHM causes exponential 
amplification of the mutated plasmid to increase the efficiency of transformation by increasing the 
yield of the reaction.  Before the primers are added to the PCR reaction, they are phosphorylated so 
that the PCR product can later be ligated to form a closed circle. After ligation is complete, the 
circularized DNA can be transformed into bacterial cells. Figure 10 illustrates how RTHM operates.  
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Figure 10: The Process of ‘Round the Horn Mutagenesis. A) Phosphorylated primers containing the targeted point 
mutations are used to amplify the parent vector at the site of the gene of interest via PCR. B) The parent plasmid DNA 
is degraded using Dpn1. The remaining product contains two phosphorylated ends where the primers annealed along 
the target gene, including the desired mutations. C) The phosphorylated ends are ligated to form the complete plasmid, 
with the target gene in tact and containing the point mutations. 
 
The primer phosphorylation reaction was the first step in the standard RTHM protocol. The 
primer stocks were at 100μM in water. Then the following was mixed together for each primer, for a 
total volume of 50μL: 37μL of H2O, 5μL of 10 Kinase reaction buffer, 1μL 50mM MgSO4, 5μL of 
100μM primer, 1μL 100mM ATP, and 1μL T4 polynucleotide kinase (PNK). This mixture was 
incubated at 37°C for 60 minutes, and then heated at 95°C for 5 minutes to kill the PNK enzyme. 
After primer phosphorylation was completed, the PCR reaction was performed. The PCR reaction 
for RTHM was modified slightly from the standard PCR reaction previously described. A RTHM 
PCR reaction contained 35μL DNAse free H2O, 10μL 5x GC Buffer, 1.5μL of the phosphorylated 
forward primer, 1.5μL of the phosphorylated reverse primer, .5μL of of 10mM dNTP, 1μL of the 
parent plasmid DNA, and .5μL Phusion® Enzyme. The specific PCR reaction, primers, and 




Table 4: LSS mCherry Primers and PCR Cycle Settings 
 
The PCR product was run on a 1% agarose gel using gel electrophoresis to confirm the 
presence of the amplified plasmid, and then 1.5μL of Dpn1 was added to the PCR product. After 
incubation with Dpn1 for 2 hours, the PCR product was ligated. The ligation reaction required that 
1.5μL of Fast-LinkTM ligation buffer, .75μL 10mM ATP, 1μL of Fast-LinkTM DNA ligase, and 
8.75μL H2O were added to 3μL of the post-Dpn1 PCR product. This mixture was incubated at 
room temperature for 30 minutes, and then the DNA ligase was heat inactivated by incubating the 
reaction tube at 70°C for 15 minutes. Following the ligation reaction, the DNA product was 
transformed into E. coli and plated on selective LB agar containing 250 μg/mL Hyg. In this 
experiment, the ligated RTHM PCR product was transformed into E. coli to amplify the circularized 
DNA containing the mutant mCherry gene. Because colony PCR screening could not be performed 
on the resulting colonies, several colonies were picked at random and cultured overnight. DNA was 
isolated from the E. coli cultures and sent for sequencing to confirm that only the desired mutations 
were made to mCherry.  
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 6.3b Creation of an LSS mCherry Strain of Msm 
 The DNA isolated from the colony containing the correctly mutated mCherry was 
transformed into WT Msm. The fluorescent properties of the LSS mCherry strain of Msm were 
analyzed using a fluorescent plate reader and compared to those of a WT mCherry strain of Msm 
and to the properties established in the literature. An excitation wavelength of 585 nm and an 
emission wavelength of 615 nm was used during this analysis. Additionally, an excitation scan from 
400nm-585nm was completed for each sample using an emission wavelength of 615 nm. Before 
analysis, the cultures were pelleted and resuspended in phosphate-buffered saline (PBS) to eliminate 
any background fluorescence from the LB Tw media in which Msm was grown.   
6.4 Aim 3 Methodology 
6.4a BiFC Overview 
 A BiFC assay provides a direct fluorescent readout of the interaction between two protein 
partners. To do this, a fluorescent protein is first split at a specific point. This point must be selected 
so that the two halves of the fluorescent protein are not fluorescent when they are on their own, but 
are capable of rejoining with one another to reform the functional fluorescent protein. Using genetic 
engineering, each of the halves is fused to one of the protein partners via a flexible linker. When the 
BiFC plasmid constructs are transformed into cells the split FP, linker, protein partner complexes 
are produced. When the protein partners interact, the halves of the FP are brought into proximity 
with each other and reconstitution of the FP occurs. The restored FP is functional and emits a 
fluorescent signal, which indicates directly that the protein partners are interacting. Fluorescence can 
be detected either by using a fluorescent microscope or with a fluorescent plate reader. For this 
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experiment, mCherry was selected to be the FP based on previous work that demonstrated split 
mCherry can form the basis of a functional mCherry BiFC in Vero cells [32].  
6.4b Creation of Split mCherry BiFC Strains 
 FastCloning was used to construct the mCherry BiFC plasmid constructs from the parent 
plasmids pUAB 100 and pUAB 400. The layout of the general mCherry BiFC constructs is detailed 
in Figure 11. It is important to note that the arrangement of the mCherry halves in these constructs 
leaves the split site interface of mCherry unattached to the glycine linker or to any other proteins; 
the split site of each half is left free to allow reconstitution to occur readily (See Figure 12). This 
feature was maintained within all of the mCherry BiFC constructs to mimic the constructs that were 
shown to be functional in Vero cells [32]. Two pairs of protein partners were selected as proof-of-
principle PPIs for the mCherry BiFC constructs based on their high level of interaction according to 
previously collected M-PFC data. The M-PFC is the most similar assay to BiFC currently available in 
mycobacteria, which is why M-PFC data was used to make predictions about the BiFC constructs.   
 
Figure 11: General Designs for the mCherry BiFC Plasmids. The arrangements of the mCherry fragments and the 





Figure 12: The Crystal Structure of mCherry, Including The Split Site Used for BiFC. The blue and red portions 
of the structure indicate the two fragments of mCherry produced upon splitting the protein at amino acid 159. These 
fragments reconstitute in a functional BiFC assay to produce a fluorescent signal.  
 
The first interaction pair selected was the General Control Protein (GCN4) homodimer, 
which has demonstrated the strongest PPI in the M-PFC thus far and is regularly used as a strongly 
positive control in the M-PFC assay. GCN4 is not a mycobacterial protein, rather it is natively found 
in the yeast Saccharomyces cerevisiae where it operates as a transcription factor [40]. The two-stranded, 
parallel coiled coil structure of the GCN4 homodimer bound to DNA is shown in Figure 13 [40, 
41]. 
 
Figure 13: The Crystal Structure of the GCN4 Homodimer, bound to DNA. The GCN4 homodimer forms a two-
stranded parallel coiled coil. 
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The second pair selected for testing the mCherry BiFC were two protein partners that make 
up the Acid and Phagosome Regulated (apr) gene locus that is unique to Mtb. Three genes are 
contained within the locus: aprA, aprB, and aprC. These genes are upregulated in Mtb growing in 
acidic conditions both in vitro and in macrophages and deleting these genes inhibits Mtb‘s ability to 
grow, thus they are believed to be important to Mtb‘s ability to survive and persist through the 
hostile conditions it encounters inside the host during infection [42]. Predictions indicated that aprA 
and aprB both encode small proteins, but little else has been concluded about their structures [42]. 
When aprA and aprB were tested in a M-PFC assay, it was found that they exhibited strong levels of 
interaction, particularly when the N-terminus of aprA was exposed to the C-terminus of aprB [43].  
 
Figure 14: A Model of the Final mCherry BiFC Constructs. Following transformation of the mCherry BiFC plasmid 
pairs into Msm, these are the protein constructs predicted to be expressed inside the cells. When interaction between the 
protein partners occurs, the mCherry fragments are brought into proximity with one another and they reconstitute to 







The configuration of aprA and aprB in the M-PFC constructs that produced this strong 
interaction is consistent with the constraints imposed by arrangement of the mCherry halves in the 
mCherry BiFC constructs. Because aprA/aprB is the strongest Mtb-exclusive PPI we have shown 
that fits this configuration and the aprA/aprB PPI is of interest as a novel drug target, this pair was 
also selected for the mChery BiFC. The aprA/aprB mCherry BiFC constructs were also made via 
FastCloning, and diagrams of the resulting protein constructs are detailed in Figure 14. The primers 
used for these FastCloning reactions are displayed in Table 5.   
 
Table 5: Primers Used to Construct the mCherry BiFC Plasmids 
 
Once the GCN4/GCN4 and aprA/aprB BiFC plasmids were FastCloned, they were 
transformed into E. coli and colony PCR screening was performed as described in section 6.2b using 
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the insert primers. After growing the positive E. coli colonies overnight and isolating the DNA, 
sequencing was performed to confirm that the constructs had been made successfully. Then the 
completed BiFC constructs were transformed into Msm, both individually and as pairs.  
6.4c BiFC Analysis 
 According to the literature, mCherry does not reconstitute well at 37°C, so following 
mCherry BiFC culture growth, cells must be incubated at room temperature (~25°C) overnight or at 
4°C for 1-2 hours before reconstitution occurs [32]. The Msm BiFC cultures were grown at room 
temperature or at 37°C for three days. After diluting the cultures to equal ODs, they were 
distributed into 500μL aliquots and either left at room temperature or placed in a 4°C refrigerator 
for intervals between 1 hour and overnight. At each interval, both the room temperature and 4°C 
BiFC samples were examined for fluorescence in the fluorescent plate reader, using an excitation 









CHAPTER SEVEN: RESULTS 
 In an effort to improve our ability to study Mtb-specific PPI and to screen for new TB 
drugs, three new fluorescence-based tools were investigated in Msm. First an M-PFC assay was 
created to analyze the PPI of the GyrA homodimer in the TB gyrase complex. Then, the potential 
for translating this assay into a green fluorescent M-PFC assay was examined, in an effort to 
streamline the assay. The other two tools were focused on applications of the red fluorescent protein 
mCherry. To improve the sensitivity of assays that rely on mCherry-based readouts, altering 
mCherry‘s spectral properties to generate a large Stokes shifted mutant was desirable. Mutations 
were made to the mCherry gene, replicating alterations that generate LSS mCherry in E. coli [27]. 
Spectral characteristics of our mCherry mutant in Msm were subsequently analyzed. To create a 
more diverse assay that is capable of studying mycobacterial PPI with a direct fluorescent readout, 
an mCherry BiFC system was created based on one previously constructed in mammalian cells [32]. 
Proof-of-concept of this assay was then tested using two distinct PPI pairs. Overall, these 
fluorescent tools were designed to improve the quality of the assays used to study PPI in Mtb so that 
enhanced drug screening platforms can be developed to discover antibiotics that combat TB better 
than those currently available.  
7.1 Aim 1: TB Gyrase A and Fluorescent M-PFC 
 A GyrA/GyrA M-PFC assay was created to determine whether GyrA dimerization is 
detectable via M-PFC and to measure the strength of the interaction between the GyrA homodimer 
in the TB gyrase complex. Genetic engineering, transformation of the M-PFC constructs into Msm, 
and measurement of the relative interaction strength of the GyrA/GyrA pair were used as described 
above. The pUAB plasmids used to construct this assay were provided to our lab by Dr. Adrie Steyn 
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from the University of Alabama. Proof-of-concept of the M-PFC assay was demonstrated in 
previous experiments [17, 18] and the assay has since been modified and used successfully to 
characterize the strengths of a variety of protein partners in our lab [43].  
 To construct the GyrA/GyrA M-PFC strains, several steps were required. First, genetic 
engineering was used to generate the pair of target plasmids by modifying pUAB300 and pUAB400. 
Models of the target M-PFC plasmids shown in Figure 9 (GyrA_pUAB300 and GyrA_pUAB400) 
were constructed. On each target plasmid, the GyrA gene was fused via a flexible glycine linker to 
one domain of the DHFR reporter protein Based on these models, primers were designed to 
amplify the vectors and GyrA fragments needed for FastCloning. The vectors and fragments were 
amplified via PCR and their identities were confirmed on an agarose gel based on their respective 
sizes, in base pairs. The GyrA fragments were 2517 base pairs in length, the pUAB300 vector was 
4895 base pairs, and the pUAB400 vector was 4703 base pairs. These sizes could be clearly 
distinguished using the GeneRuler 1 kb DNA ladder on the agarose gel, as previously described. 
Next, the two vector and fragment pairs were fused together using FastCloning. The FastCloning 
products were transformed into E. coli to amplify the GyrA_300 and GyrA_400 plasmids. Following 
isolation of the plasmid DNA and positive confirmation by sequencing (data not shown) the 
plasmids were transformed into Msm individually and together as a pair. Once the three Msm M-
PFC strains were created, the M-PFC was set up to measure the strength of the GyrA/GyrA 
interaction. Table 6 provides a description of the strains used in this assay. The two negative control 
strains, consisting of only one half of the PPI pair on its own in Msm, were included to ensure that 
neither construct alone was responsible for results indicating interaction in the 
GyrA_300+GyrA_400 strain. The positive DosR/DosR control was included because it is another 
M-PFC strain in which PPI have previously been confirmed using the same assay. DosR/DosR was 
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selected specifically because it exhibits moderate-strength PPI, similar to the strength expected of 
the GyrA/GyrA PPI.  
Table 6: Strains Utilized During the GyrA/GyrA M-PFC Assay 










































 The GyrA/GyrA M-PFC assay was run several times until conditions were optimized, 
minimizing variation between runs. It became evident that a critical factor in attaining consistency 
between repeats of the assay was creation of fresh TRIM stocks for each run. A qualitative 
measurement of the strength of the GyrA/GyrA PPI can be observed by observing the color 
change from blue to pink in each well visually. An example can be seen in Figure 15, which is a 
representative example of a GyrA/GyrA M-PFC assay result. Compared to negative control strains, 
the GyrA_300+GyrA_400 strains survive (appear pink or purple) at a higher concentration of 
TRIM, indicating that they are positive for PPI between GyrA.  
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Figure 15: A Representative Example of the Visual Results of the GyrA/GyrA M-PFC Assay. After the cultures 
are grown in the presence of two-fold diluted concentrations of TRIM in a 96 well plate, Alamar blue dye is added to all 
of the wells. This diagram shows the appearance of the wells following the standard two hour incubation at 37°C with 
Alamar blue. 
 
During each assay, the GyrA_300+GyrA_400 strain exposed to the full range of TRIM 
concentrations was run twice to increase the accuracy of the results. Two additional columns were 
included in each assay: GyrA_300+GyrA_400 exposed to the maximum concentration of TRIM 
(50ug/mL) and GyrA_300+GyrA_400 exposed to no TRIM. The column exposed to the maximum 
amount of TRIM was used to calculate the background of each plate during quantitative analysis of 
the assay (described later). The column exposed to no TRIM was included to measure the maximum 
signal so that the experimental wells could be calculated as a percentage of the maximum signal for 
each plate.  
To perform quantitative analysis of the GyrA/GyrA M-PFC assay, each plate was read in a 
fluorescent plate reader to quantify the fluorescent signal due to reduced Resazurin in the wells for 
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each column relative to the LB Tween control wells. A quantitative map is generated from this for 
each plate, displaying the fluorescent signal of the wells in Relative Fluorescence Units (RFUs). All 
plates were read using the same settings on the plate reader to ensure the RFU readings were scaled 
consistently. An example is shown in Figure 16. The map, like the visual result shown above, reflects 
the strength of the GyrA/GyrA PPI; however, it provides much more specific data about the 
presence of PPI in the strains. Quantitative maps were collected for three representative runs of the 
assay, and then used to assess the quality of the assay and the strength of the GyrA/GyrA PPI.  
 
Figure 16: The Quantitative M-PFC Map. This figure is an example of the quantitative map generated by reading an 
M-PFC plate in a fluorescent plate reader. This data is necessary to analyze the quality of the assay. 
 
In all three maps, as in Figure 14, 6.25ug/mL is the concentration of TRIM at which a 
GyrA_300+GyrA_400 can be distinguished from the negative controls. Therefore, 6.25ug/mL 
TRIM was selected as the optimal screening point of this assay, were it to be used to screen for 
compounds that inhibit the GyrA/GyrA partnership. With this goal in mind, calculations assessing 
the quality of the assay were performed using data collected at the screening point. First, the signal-
to-background ratio was calculated by averaging the fluorescence values at 6.25ug/mL TRIM for 
GyrA_300, GyrA_400, GyrA_300+GyrA_400, and the DosR/DosR control and dividing these 
averages by the background signal. The background was calculated by averaging the values of the 
 61 
wells in the 50ug/mL TRIM columns. For each plate one outlier was excluded because they were 
likely generated by slight contamination from a neighboring well and were not representative of the 
background signal. The Z‘-factor of the assay was also calculated at the screening point. The Z‘-
factor is a coefficient used to determine the range within which a signal is significant for an assay, 
which also reflects the quality of the assay.  It is calculated from the standard deviations and the 
averages of the positive and negative controls of a single run of the assay. The Z‘-factors of multiple 
plates are then averaged to generate a representative Z‘-factor. The result is a number between 0 and 
1; an assay with a result above 0.5 is judged to be well-suited for HTS applications. The Z‘-factor 
formula is shown and explained in Figure 17 [14].  
 
Figure 17: The Z’-factor formula. The standard deviations are represented byσand the averages are represented by µ. 
The subscripts refer to these values for the positive (+c) and negative (-c) controls.  
 
The signal-to-background results and the Z‘-factor are shown in Figure 18. The signal of the 
GyrA_300+GyrA_400 strain at the screening point is nearly 21 times greater than the background 
(the signal generated when the bacteria are completely killed by 50ug/mL TRIM). This is 23 times 
greater than the signal-to-background of the GyrA_300 negative control and 7 times greater than the 
GyrA_400 negative control. This indicates that at the screening point, the presence of the 
GyrA/GyrA PPI can be very clearly detected, and is easily distinguished from the assay‘s negative 
controls. It is unusual that the signal of the GyrA_400 control is closer to the GyrA_300+GyrA_400 
signal than the GyrA_300 control. However, because there is no way DHFR could be more active in 
the GyrA_400 control, this observation would likely diminish as more repetitions of the screen are 
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performed. Calculated from the same three representative plates, the Z‘-factor of this assay is .582 
which indicates that the assay is high enough quality to be used in a HTS application in the future 
but is not of exceptional quality. It is likely that the Z‘-factor could be improved substantially if 
further measures were taken to optimize the screening conditions, including the number of days the 
bacteria are grown in TRIM, the starting OD of the bacteria, and the precision of the volumes added 
to each well by using automated liquid dispensers. This assay may also be improved by inserting a 
stronger promoter in place of Hsp60 to increase the production of the M-PFC constructs in the 
bacteria.   
 
Figure 18: The Signal-to-Background and Z’-factor Results of the GyrA/GyrA M-PFC Assay. 
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 Following the success of the GyrA/GyrA M-PFC, designs to convert the assay to a GFP-
based fluorescent M-PFC were constructed. Models of the GyrA_pUAB300 and GyrA_pUAB400 
plasmids were altered to include the GFP gene, inserted following a constitutive promoter (Hsp60) 
on both plasmids. The GyrA_GFP plasmids are shown in Figure 19. Primers were designed for 
amplifying the vectors and inserts via PCR according to the GyrA_GFP models. The vectors for 
constructing the fluorescent M-PFC plasmids were amplifying the GyrA_pUAB300 and 
GyrA_pUAB400 plasmids, and the GFP fragments were amplified from the pvvRG and 
 
Figure 19: Designs for the GFP GyrA/GyrA M-PFC Plasmids 
  
pUAB400_GFP plasmids. The presence of the vectors and fragments was confirmed on an agarose 
gel based on size. Then the GyrA_pUAB300 vector was FastCloned with the GFP fragment from 
pvvRG, and the GyrA_pUAB400 vector was FastCloned with the GFP fragment from 
pUAB400_GFP. Recently, the FastCloning products were transformed into E. coli, and plated on 
selective media. Colony PCR screening was performed, and thus far only colonies from the 
GFP_GyrA_pUAB300 transformation were positive for GFP. Further attempts at acquiring GFP 
positive GFP_GyrA_pUAB400 E. coli are ongoing. In the meantime, the GFP_GyrA_pUAB300 
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positive colonies were grown overnight to amplify the DNA. The DNA was isolated from the 
cultures and transformed into Msm already containing GyrA_400, which was plated on selective 
media. The colonies on the resulting plates, unusually, were both yellow and white. GFP-positive 
Msm may appear yellow when plated as a lawn, but isolated colonies do not typically produce high 
enough levels of fluorescence to appear yellow. Therefore, three colonies were selected and grown 
in cultures: a bright yellow colony, a weakly yellow colony, and a white colony. A negative control 
culture, GyrA_300+GyrA_400, was also grown. These cultures were examined for green 
fluorescence on a fluorescent plate reader after three days of growth. The ODs of the cultures were 
normalized, and then 500uL of each culture was pelleted and resuspended in 100uL of PBS Tween 
to eliminate background signal from LB Tween. A PBS control was also included, and the 
fluorescent signals of the cultures were scaled to this negative control. A positive GFP control was 
not examined during this initial screen, but under similar conditions and at a similar OD, an Msm 
strain containing the pvvRG plasmid expresses GFP signal that is ~25 times brighter than the 
background signal from PBS Tween. Although all of the GFP_GyrA_300+GyrA_400 colonies did 
exhibit higher fluorescence than the GyrA_300 negative control, even the highest signal (Colony 1) 
was only 2.27 times brighter than negative control. The signal-to-background of the colonies is 
shown in Figure 20.  
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Figure 20: Green Fluorescence of the GFP_GyrA_300+GyrA_400 Colonies. These colonies were analyzed to 
determine whether the insertion of GFP on the GyrA_pUAB 300 plasmid produces a green fluorescent signal that is 
sufficient for strains containing this plasmid to be used in a fluorescent GyrA/GyrA M-PFC assay. 
 
Because it is typically expected that a fluorescent protein inserted onto a plasmid vector will have a 
signal-to-background value many times higher than this and because the plate contained multiple 
morphologies, all three colonies were PCR screened for GFP to confirm that they contained 
GFP_GyrA_300+GyrA_400 in Msm and were not merely contaminants or false positives. Using 
the same colony screening protocol used on E. coli, it was found that only Colony 3 contained the 
GFP gene. Therefore, from this preliminary experiment, it appears that the 
GFP_GyrA_300+GyrA_400 Msm strain does not emit a high enough fluorescent signal to be 
applied to a fluorescent M-PFC. Due to time constraints, sequencing of this plasmid was not 
performed, so it is possible that a mutation in the GFP gene or the inserted promoter is causing the 
absence of fluorescence. Sequencing should be performed to rule this out, after which alternative 
approaches could be taken to improve the fluorescent signal. Creating a double GFP (GFP-
GyrA_300+GFP_GyrA_400) Msm strain, with GFP on both the chromosomal and episomal 
plasmids, may improve the quality of the signal. This is likely since GFP would be expressed on both 
the chromosomal and the episomal plasmids, instead of just on the episomal. Another potential 
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approach would be to substitute the Hsp60 promoter on both constructs for a stronger promoter, 
like the smyc promoter used to increase the production of mCherry in the mCherry fluorescent M-
PFC. Selecting a fluorescent protein that does not have an excitation wavelength in the GFP range 
may also improve the readout of the assay because Msm and the LB Tween media it is grown in 
does exhibit higher than ideal background signal in this range.  
7.2 Aim 2: LSS mCherry 
 Based on knowledge of other LSS FPs, two amino acids within the mCherry gene were 
strategically mutated to generate LSS mCherry, which was expressed in E. coli [27]. In E. coli, LSS 
mCherry exhibited levels of fluorescence comparable to those of wild type mCherry, but its 
maximum excitation wavelength shifted from 587nm to 456nm (see Figure 21) [27]. RTHM primers 
were designed to replicate these mutations, generating a serine at amino acid 158 and a glutamate at 
amino acid 160 by in an mCherry gene that is codon optimized for expression in mycobacteria. To 
exchange these amino acids, a T was replaced with a G at base pair 497 of mCherry and a C was 
replaced with a G at base pair 502 [27]. To make these two point mutations, RTHM was performed  
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Figure 21: The Spectral Properties of Large Stokes Shift mCherry Due to Two Amino Acid Mutations 
using pvvRG as a vector, which contains the codon optimized mCherry gene. The RTHM product 
was transformed into E. coli to amplify the DNA, and then the DNA was sequenced to confirm that 
only the target point mutations had been made to the mCherry gene (See Figure 22). Sequencing was 
also performed to ensure no mutations to the promoter region were made and the stop codon of the 
 
Figure 22: Alignment of the LSS mCherry Mutant DNA to the Target Sequence. This sequence data confirmed 
that the desired two point mutations to the mCherry gene were made, and no other mutations were present in the rest of 
the gene or its promoter region (data not shown). 
 
 mCherry mutant was in tact. Then, the LSS mCherry DNA was transformed into Msm and cultures 
of the LSS mCherry strain were grown from three colonies of the single transformation, along with a 
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culture containing a strain positive for wild type mCherry. These cultures were then pelleted, 
resuspended in PBS Tween, and screened for their excitation spectra at an emission of 610nm using 
a fluorescent plate reader. The excitation spectra of the three colonies were averaged and a graph 
comparing the LSS mCherry mutant in Msm to a control containing PBS alone and the positive 
mCherry control is found in Figure 23. As the figure shows, the LSS mCherry contains neither a 
significant excitation peak at 456nm as predicted, nor an excitation peak at 587nm as wild type 
mCherry does. Rather, no significant excitation peak was observed in the LSS mCherry mutant, 
while an excitation peak is clearly observed in the wild type mCherry control at ~587nm.  
 
Figure 23: An Excitation Scan Comparing the LSS mCherry Mutant to Wild Type mCherry. This excitation scan 
was performed from 400nm through 585nm for an emission wavelength of 615nm to examine the spectral properties of 
the mutant mCherry to those of the wild type. 
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 These observations can be explained in several ways. For example, it is possible that the 
mutations to the mCherry gene cause the protein to misfold or to be degraded, due to differences in 
the Msm cell environment compared to the environment inside E. coli. To determine whether this 
hypothesis is true, a Western Blot could be done to test for the presence of mCherry. This step was 
not performed during this project because, while it might have helped explain the observations, it 
would not have altered the fact that this LSS mCherry mutant is not useful to us in Msm. It also was 
not performed because we do not currently have either an antibody or a tag on mCherry. Another 
approach to improve the outcome of this aim is to make different point mutations to the mCherry 
gene. A different set of amino acid substitutions generated another LSS mCherry mutant in E. coli 
and this alternate mutant may be expressed more successfully in Msm than the first mutant [27].  
7.3 Aim 3: The Split mCherry BiFC 
 Two sets of mCherry BiFC plasmids were designed to attempt proof-of-concept of the 
mCherry BiFC with two different PPIs: GCN4/GCN4 and AprA/AprB. These two PPIs have 
previously been identified for having strong interactions using the M-PFC assay [43]. First, from the 
plasmids pUAB 100 and pUAB 400, the split mCherry plasmids pUAB100_mCh and 
pUAB400_mCh were designed. Primers were made to amplify the mCherry gene in two fragments, 
split between amino acids 159 and 160 [32]. N-terminal mCherry (amino acids 1-159) was inserted 
into the pUAB 400 vector, and C-terminal mCherry (amino acids 160-236) was inserted into the 
PCR amplified pUAB 100 vector through FastCloning. The pUAB 400 and pUAB 100 vectors used 
already contained GCN4 in the PP1 and PP2 positions. Also, the N-terminal and C-terminal 
mCherry fragments took the place of the DHFR A and DHFR B fragments in these plasmids. These 
new constructs were transformed into E. coli, amplified, isolated, and sequenced. Following sequence 
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confirmation, the process of creating the target GCN4 BiFC constructs (GCN4_pUAB 100_mCh 
and GCN4_pUAB 400_mCh was complete). For each of the final AprA and AprB constructs, 
primers were designed to amplify the fragments (AprB and AprB) and vectors (GCN4_pUAB 
100_mCh and GCN4_pUAB 400_mCh) via PCR. Then the presence of the fragments and vectors 
were confirmed on an agarose gel by size and FastCloned together to create the target plasmids. The 
FastCloning products were transformed into E. coli to amplify the DNA, and sequencing was 
performed on the two new constructs to ensure they matched those modeled in Figure 24.  
  
Figure 24: Completed mCherry BiFC Plasmids 
 
The plasmids were then transformed into Msm in pairs: GCN4_pUAB 100_mCh with 
GCN4_pUAB 400_mCh, and AprB_pUA B400_mCh with AprA_pUAB 100_mCh. Individual 
control strains were also generated, although better controls for the BiFC technique exist and will be 




Table 7: The Msm Strains Examined for Proof-of-Principle of the mCherry BiFC 




































































 The first mCherry BiFC strains designed and completed were the GCN4/GCN4 strains 
because GCN4/GCN4 is a stronger PPI than AprA/AprB according to previous M-PFC data [43]. 
More is also known about the structure of GCN4, which is necessary when creating the ideal 
negative controls for a BiFC assay. Ideal negative controls for a BiFC assay are strains that contain 
BiFC constructs in which the interaction interface between PP1 and PP2 has been strategically 
mutated to interrupt their interaction, but to generate these controls the structure of the partners 
should be well understood [28]. These ideal negative controls are only truly necessary to rule out 
false positive signals from a BiFC assay because they confirm that a positive signal was not due to 
non-specific interactions generated from unanticipated associations with the BiFC protein constructs 
[28]. Rather than expending considerable resources to generate these ideal negative controls at the 
outset of the project, alternative negative control strains were constructed instead. If a positive signal 
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were generated from the GCN4/GCN4 BiFC strains being examined for proof-of-principle, then 
the ideal negative controls would have been engineered to ensure the validity of the signal. The 
alternative negative control strains examined in this experiment were GCN4_100_mCh and 
GCN4_400_mCh, generated by transforming either the episomal or the chromosomal plasmid alone 
into Msm. Each of these strains contains only one half of the split mCherry protein fused to one of 
the protein partners. Thus, these strains are negative controls in that they reflect the signal produced 
when only one of these constructs is present at a time and in that they should produce no signal at 
all. A strain containing intact mCherry on both the episomal and chromosomal plasmids, producing 
mCherry constitutively, was also used during this experiment as a positive control for the signal 
produced by functional mCherry (what a positive BiFC signal should look like).  
 Assessment of the GCN4/GCN4 BiFC strain, along with the negative and positive control 
strains, was performed as described previously, and the level of fluorescence of the strains relative to 
the background over time is shown in Figure 25. As already mentioned, split mCherry does not 
reconstitute well at 37°C. Rather, cells must be incubated at room temperature (~25°C) overnight or 
at 4°C for 1-2 hours before reconstitution is observed. Therefore, fluorescence was assessed at both 
room temperature and 4°C, and periodically over a span of 1-24 hours to ensure any reasonably 
expected signal was not overlooked. At both temperatures and across all time points, no signal from 
the GCN4/GCN4 BiFC stain sufficiently similar to the signal of the positive control was observed. 
Although the GCN4/GCN4 homodimer is a strong PPI, its leucine zipper structure may explain the 
negative BiFC results. The mCherry fragments must be arranged on the BiFC constructs so that the 
end of the N-terminal fragment is exposed to the beginning of the C-terminal fragment. This 




Figure 25: Red Fluorescent Signal Produced by the GCN4/GCN4 BiFC Over Time When Strains Were 
Incubated at Room Temperature and at 4°C. 
 
When these constructs are expressed and the GCN4 portions dimerize, the mCherry N-terminal and 
C-terminal fragments are separated across the leucine zipper from one another (See Figure 26 for 
illustration). It is possible that this arrangement does not allow adequate proximity of the mCherry 
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fragments, so reconstitution does not occur, even though this length was sufficient for DHFR A and 
B reconstitution. Increasing the length of the glycine linker may solve this problem by increasing the  
 
Figure 26: Hypothetical Illustration of Structural Issues Preventing Success of the GCN4/GCN4 BiFC 
distance across which the fragments are free to move, increasing the likelihood that the non-
fluorescent fragments will meet and reconstitute mCherry. Because alternative plasmids with many 
different lengths of glycine linkers would need to be constructed to examine this hypothesis, this 
route was not pursued due to time constraints. Instead, the focus of the project shifted to testing the 
BiFC on a pair of much smaller protein partners (AprA and AprB), which were already of interest 
and seemed unlikely to pose the same hypothesized problems as the GCN4/GCN4 BiFC.  
 The AprA/AprB BiFC strain was designed based on previous M-PFC data that 
demonstrated significant interaction between the protein partners, as long as the C-terminus of AprB 
remained free (See Figure 27) [43]. In accordance with this requirement, AprA was inserted in 
GCN4‘s  place on the GCN4_pUAB 100_mCh plasmid and AprB was inserted in GCN4‘s place on 
the GCN4_pUAB 400_mCh plasmid. These plasmids were used to construct the AprA/AprB BiFC 
strain. Negative controls analogous to those selected for the GCN4/GCN4 BiFC experiment were 
also made, so that AprA_pUAB 100_mCh and AprB_pUAB 400_mCh were each transformed alone 
into Msm. The same positive control was used as in the GCN4/GCN4 BiFC experiment. 
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Figure 27: AprA/AprB M-PFC Data. The AprA/AprB PPI is strong when the C-terminal of AprB is free to interact 
with AprA. 
After the AprA/AprB BiFC strain, the negative control strains, and the positive control were 
grown, the same protocol used to analyze the signal over time for the GCN4/GCN4 BiFC was used 
to assess the AprA/AprB BiFC. The fluorescence of the strains relative to the background over time 
for both room temperature and 4°C are shown in Figure 28. The AprA_100_mCh strain did not 
grow sufficiently, so it could not be included in this analysis.  
Like with the GCN4/GCN4 BiFC, at both temperatures and across all time points, no signal 
from the AprA/AprB BiFC strain sufficiently similar to the signal of the positive control was 
observed. While the glycine linker length may also be the problem in the AprA/AprB BiFC, it is 
possible that other issues explain the lack of signal. For example, the complete BiFC protein 
constructs (the protein partner, plus the glycine linker, plus the mCherry fragment) may not be 
expressed well in Msm. Also, the temperature and time required to reconstitute mCherry in Msm 
may differ from those required in the Vero cells in which it was originally studied. An alternative 
approach might first select a different split FP that is known to reconstitute readily at 37°C to 





Figure 28: Red Fluorescent Signal Produced by the AprA/AprB BiFC Over Time When Strains Were 




CHAPTER EIGHT: DISCUSSION 
 The persistent and growing threat to global health of TB and drug-resistant TB is 
exacerbated by the impractical drug treatments currently available and a lack of new, more effective 
antibiotics to replace them. Though efforts have been made to develop better treatments, the 
pipeline of TB drug development remains slow, and innovative, optimized drug-screening platforms 
are needed. Knowledge about the PPI necessary to Mtb‘s pathogenesis is still largely lacking, but 
great potential lies in developing drug screening techniques that are amenable to HTS and combine 
the benefits of target-based screening for novel PPI with the benefits of whole cell screening. 
Therefore, engineering tools that improve our ability to validate PPI necessary for Mtb to cause 
disease under host-like conditions and also improve our ability to screen for compounds that disrupt 
these PPI is a promising step toward discovering novel drug therapies to treat TB.  
This project‘s aims were focused on creating tools to advance the study of PPI in Mtb and to 
improve the quality of current PPI-based TB drug screening platforms. First, a new PPI assay 
applicable to HTS was generated: the GyrA/GyrA M-PFC. Gyrase A is an essential target in Mtb 
that is of interest for drug screening. Future work will optimize this assay further to improve its 
quality, after which it can be used to study the efficacy of a library of compounds at disrupting the 
GyrA/GyrA dimer interface. With this future application in mind, attempts were made to streamline 
the M-PFC assay readout.  
To transition away from a viability readout requiring the addition of Alamar blue dye and an 
additional incubation, the GyrA/GyrA M-PFC plasmids were endowed with GFP following a 
constitutive promoter region. The fluorescent signal produced by the GFP_GyrA episomal plasmid 
alone was not yet sufficient to apply the strain to a fluorescent M-PFC assay. Future work on this 
aspect of the project would test the fluorescent signal produced when GFP was present on both the 
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episomal and chromosomal plasmids of the GyrA/GyrA M-PFC, and a stronger promoter region 
may be inserted in front of the GFP gene to increase the signal further. If the signal of the improved 
fluorescent M-PFC strain reached a sufficiently detectable level, then the quality of the fluorescent 
M-PFC would be compared alongside the original GyrA/GyrA M-PFC. A high quality GFP 
GyrA/GyrA M-PFC could later be applied to HTS.  
Two different red-fluorescent tools were also assessed: LSS mCherry and the mCherry BiFC. 
The spectral properties of LSS mCherry hold the potential to improve the sensitivity of assays that 
rely on mCherry for their readout, like the mCherry-based M-PFC. Mutations to the mCherry gene 
were made to mimic those that generated an LSS mCherry protein in E. coli; however, mutating the 
mycobacterial-optimized mCherry gene and transforming this construct into Msm did not produce a 
strain exhibiting LSS mCherry fluorescence. Future work on this project might determine whether 
other mutations to the mCherry gene previously shown to generate LSS mCherry in E. coli can 
generate LSS mCherry in Msm. Alternately, mutations shown to produce to a different LSS FP may 
be investigated to determine whether an LSS FP other than mCherry can be engineered and will be 
expressed more readily in Msm.  
The final tool investigated was the mCherry BiFC, originally demonstrated in Vero cells. 
BiFC in theory provides advantages compared to current Mtb PPI assays like the M-PFC because its 
readout directly reflects the presence of PPI. Though BiFC has been successfully applied to many 
cell types and a variety of protein partners, proof of principle was not achieved in mycobacteria 
during this project. Two distinct protein pairs (GCN4/GCN4 and AprA/AprB), which show strong 
interaction in the M-PFC assay, were used to test the mCherry BiFC. Neither of these partnerships 
produced the expected fluorescent readout, and much of the future work on this project would 
likely be focused on determining the explanation for this through trying alternative split FPs that 
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more easily reconstitute at 37°C, testing different linker regions, and ensuring expression levels of 
the protein partner constructs are not compromised.   
The final outcome of this project is a functional PPI assay for the Gyrase A homodimer, 
which can swiftly be translated to a new HTS drug screening platform for this highly relevant target. 
This may lead to the discovery of new treatment options for drug-resistant TB in the future, which 
would lend further credibility to the idea that developing TB drug screening platforms that target 
PPI is an innovative and favorable endeavor. While the fluorescent tools investigated during this 
project are not yet functional, much of the work necessary to determine whether their application to 
Mtb is ultimately feasible has been completed. Additionally, the process of engineering them 
provided helpful insight into the difficulties of designing tools like this and applying them to Mtb in 
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